{"study_id": 103099, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the impact of Cornus mas L. fruit extract (CMFE) on liver function markers, including alanine aminotransferase, in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found a significant decrease in CK-18 levels in the CMFE group but no significant difference between groups for other markers. A significant increase in fibrosis score was observed in the placebo group, with a notable difference between groups after 12 weeks.", "population_specificity": "Fifty patients with NAFLD.", "effective_dosage": "20 ml of CMFE or placebo daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:59.571227+00:00"}
{"study_id": 103092, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to discuss the potential of cytokeratin-18 (CK18) as a biomarker for drug-induced liver injury (DILI) and its advantages over traditional markers like alanine aminotransferase (ALT).", "results_summary": "The abstract highlights that CK18, particularly its full-length and cleaved forms, shows promise in diagnosing early-stage DILI and understanding hepatocellular injury mechanisms, but its role in preclinical models, especially in vivo rat models, remains understudied.", "population_specificity": "Preclinical and clinical drug therapy settings (focus on hepatotoxicity in drug development).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:59.926266+00:00"}
{"study_id": 103093, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to compare the efficacy and safety of tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF) in reducing HBV vertical transmission, not specifically evaluating alanine.", "results_summary": "The study found no significant differences in alanine aminotransferase levels between TAF and TDF groups, but it did not focus on alanine's effects.", "population_specificity": "Pregnant women with HBV infection.", "effective_dosage": "Not applicable (study focused on TAF and TDF, not alanine).", "study_duration": "Not specified for alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:00.203490+00:00"}
{"study_id": 103098, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to improve the evaluation criteria for drug-induced liver injury (DILI) by examining serum metabolomic changes, including alanine aminotransferase (ALT), to better characterize DILI phenotypes and monitor progression.", "results_summary": "The study found that free and conjugated bile acids and glycerophospholipids were key metabolites for DILI phenotype characterization. Metabolomic data integrated into a ternary diagram improved DILI phenotyping, severity assessment, and progression monitoring compared to traditional ALT and ALP classification.", "population_specificity": "79 DILI patients recruited and monitored using established clinical criteria.", "effective_dosage": "Not specified", "study_duration": "Monitored along the course of the disease until recovery (duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:00.253624+00:00"}
{"study_id": 103091, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a herbal supplement containing Gynostemma pentaphyllum (Gpp) extract (ActivAMP\u00ae) could improve body composition in overweight males and females, including effects on fat mass and distribution.", "results_summary": "The Gpp group showed significant reductions in total body weight, body mass index, total fat mass, and gynoid fat mass compared to placebo. Blood measures indicated statistically significant differences in plasma triglyceride, alanine aminotransferase, and tumour necrosis factor-\u03b1 levels between groups.", "population_specificity": "Overweight and obese men and women aged over 18 years.", "effective_dosage": "Not specified", "study_duration": "16 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:00.297089+00:00"}
{"study_id": 103097, "supplement_id": 863, "safety_score": "30", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the hepatotoxicity risk of new-generation BCR-ABL TKIs (including effects on alanine aminotransferase levels) with imatinib and assess their clinical benefits in CML patients.", "results_summary": "New-generation TKIs (except dasatinib) showed significantly higher risks of ALT and AST elevation (all grades and high-grade) compared to imatinib, but also achieved higher major molecular response rates at 1 year. No difference in 1-year overall survival was observed.", "population_specificity": "3,475 CML patients (median age 49, 59.2% male) from randomized phase 2/3 clinical trials.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:00.580970+00:00"}
{"study_id": 103100, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and antiviral activity of RO7049389 (a hepatitis B virus core protein allosteric modulator) in patients with chronic HBV infection.", "results_summary": "RO7049389 was safe and well tolerated, with mild to moderate adverse events (e.g., headache, increased ALT/AST). It demonstrated antiviral activity, reducing HBV DNA levels by 2.44 log after 4 weeks of treatment.", "population_specificity": "Patients with chronic HBV infection not currently on anti-HBV therapy, enrolled across 11 liver disease centres in Hong Kong, New Zealand, Singapore, Taiwan, and Thailand.", "effective_dosage": "200 mg or 400 mg twice daily, or 200 mg, 600 mg, or 1000 mg once daily.", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:00.878822+00:00"}
{"study_id": 103094, "supplement_id": 863, "safety_score": "36", "efficacy_score": 75, "quality_score": 82, "study_goal": "The researchers assessed the safety and growth impact of nilotinib treatment, including its effect on alanine transferase levels, in pediatric patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML).", "results_summary": "The study found that nilotinib treatment was associated with attenuated growth rates in pediatric patients, with a median decrease in height SDS. Increased alanine transferase (36.2%) was among the most common adverse events, indicating potential liver-related side effects.", "population_specificity": "Pediatric patients with Philadelphia chromosome-positive CML, either newly diagnosed or resistant/intolerant to imatinib/dasatinib.", "effective_dosage": "230 mg/m\u00b2 twice daily", "study_duration": "\u226548, 28-day treatment cycles (approximately 3.7 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:01.586259+00:00"}
{"study_id": 103103, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of alanine and other metabolites in the metabolic shifts associated with depression and the efficacy of Chinese herbal medicine (CHM) in treating depressive disorders.", "results_summary": "The study found that CHM treatment significantly altered metabolic disorders in depression, including shifts in amino acids like alanine, suggesting a reorganization of metabolic networks. Alanine was implicated in amino acid metabolism changes linked to depression treatment.", "population_specificity": "Animals and clinical populations with depressive disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:08.366590+00:00"}
{"study_id": 103108, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to systematically review and meta-analyze RCTs investigating the effect of the Mediterranean diet on liver enzymes, including Alanine, in relation to NAFLD.", "results_summary": "The study reviewed ten RCTs but found contradictory results regarding the effects of the Mediterranean diet on liver enzymes like Alanine, indicating mixed outcomes.", "population_specificity": "General population with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:08.600069+00:00"}
{"study_id": 103104, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effect of SGLT2 inhibitors on alanine transaminase levels and other markers in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease.", "results_summary": "SGLT2 inhibitors significantly reduced alanine transaminase levels, hepatic fat, and improved body composition in patients with T2DM and NAFLD. The reductions were statistically significant and clinically relevant.", "population_specificity": "Patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:08.782839+00:00"}
{"study_id": 103102, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to investigate the effects of glucocorticoid treatment on liver function, hospitalization length, expenses, and 28-day mortality in patients with HBV-associated acute-on-chronic liver failure (ACLF), including the role of alanine aminotransferase (ALT) levels.", "results_summary": "GC treatment did not improve liver function outcomes (higher ALT and TBil levels) but might reduce 28-day mortality. It did not shorten hospitalization length and increased expenses. Similar results were observed with or without antiviral treatment.", "population_specificity": "349 patients hospitalized with HBV-associated ACLF.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:09.800055+00:00"}
{"study_id": 103105, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the clinical and biochemical profiles of lean vs. non-lean NAFLD patients, including the role of alanine aminotransferase (ALT) levels.", "results_summary": "The study found that non-lean NAFLD patients had higher rates of elevated ALT (65.2% vs. 46.8%) and AST, along with more metabolic derangements compared to lean patients. Cirrhosis or HCC were present in 8.4% of NAFLD patients at initial consultation.", "population_specificity": "Patients diagnosed with NAFLD in two outpatient hepatology clinics in the Philippines (57.9% male, 88.1% non-lean).", "effective_dosage": "Not available", "study_duration": "Data collected from February 2007 to January 2017 (retrospective study, no specific intervention duration).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:10.707669+00:00"}
{"study_id": 103101, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the efficacy of stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib in patients with locally recurrent pancreatic cancer, not specifically to evaluate Alanine.", "results_summary": "The study found that SBRT plus pembrolizumab and trametinib improved median overall survival compared to SBRT plus gemcitabine, but Alanine was only mentioned as part of adverse effects (increased alanine aminotransferase).", "population_specificity": "Patients aged 18+ with histologically confirmed pancreatic ductal adenocarcinoma, mutant KRAS, PD-L1 positive, ECOG 0-1, and local recurrence post-surgery and chemotherapy.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up was 23.3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:10.793028+00:00"}
{"study_id": 103106, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to assess whether fasting intact insulin levels, measured by mass spectrometry, could predict NAFLD, particularly in patients without diabetes, and how this compared to other diagnostic methods.", "results_summary": "Fasting intact insulin was significantly higher in NAFLD patients, especially those without diabetes, and showed strong predictive accuracy (AUC 0.90). Combining intact insulin with ALT further improved detection (AUC 0.94), outperforming traditional noninvasive scores.", "population_specificity": "Patients with and without NAFLD (67% male, mean age 52 \u00b1 11 years, BMI 33.2 \u00b1 5.7 kg/m\u00b2, 46% with diabetes).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:10.805128+00:00"}
{"study_id": 103107, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the activity and safety of savolitinib, a selective MET tyrosine-kinase inhibitor, in patients with METex14-positive pulmonary sarcomatoid carcinoma and other NSCLC subtypes.", "results_summary": "Savolitinib demonstrated an objective response rate of 49.2% in the tumor response evaluable set, with a safety profile marked by treatment-related adverse events in all patients, including grade 3 or higher events in 46% of participants. The most frequent adverse events were increased aspartate aminotransferase, increased alanine aminotransferase, and peripheral edema.", "population_specificity": "Patients aged 18 or older with locally advanced or metastatic METex14-positive pulmonary sarcomatoid carcinoma or other NSCLC subtypes, who were MET inhibitor-naive and had measurable disease.", "effective_dosage": "600 mg (bodyweight \u226550 kg) or 400 mg (bodyweight <50 kg) orally once daily.", "study_duration": "Until disease progression, death, intolerable toxicity, or other discontinuation criteria (median follow-up of 17.6 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:11.972159+00:00"}
{"study_id": 103109, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize current trends in managing chronic hepatitis B (CHB) in pregnant women, including the role of alanine aminotransferase (ALT) levels in monitoring.", "results_summary": "The abstract highlights that ALT levels are part of additional examinations for pregnant women with CHB, but it does not report specific findings about alanine's effects. The focus is on overall CHB management, including antiviral therapy and vertical transmission prevention.", "population_specificity": "Pregnant women with chronic hepatitis B.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:16.894528+00:00"}
{"study_id": 103110, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify indicators, including alanine aminotransferase, associated with recompensation in patients with decompensated cirrhosis.", "results_summary": "Alanine aminotransferase was identified as one of the relevant indicators for distinguishing recompensated cirrhosis, contributing to a model with high accuracy (92%), specificity (86.9%), and sensitivity (92.6%).", "population_specificity": "3953 patients with decompensated cirrhosis, including subgroups with gastrointestinal bleeding, bacterial infection, hepatic encephalopathy, and ascites.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:17.795191+00:00"}
{"study_id": 103111, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the safety, pharmacokinetics, and preliminary antitumor activity of talazoparib in Japanese patients with advanced solid tumors, not specifically Alanine.", "results_summary": "The study found that talazoparib was well tolerated with no dose-limiting toxicities, but it reported increased alanine aminotransferase as a treatment-emergent adverse event in some patients.", "population_specificity": "Japanese patients with locally advanced or metastatic solid tumors resistant to/ineligible for standard therapies.", "effective_dosage": "0.75 or 1 mg once daily", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:17.833544+00:00"}
{"study_id": 103112, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the effectiveness and adverse events of OCA and fibrates (including their impact on alanine aminotransferase levels) in primary biliary cholangitis patients with insufficient response to ursodeoxycholic acid.", "results_summary": "The study found that OCA and fibrates significantly decreased alanine aminotransferase levels, with OCA showing a higher decline. Triple therapy (OCA plus fibrates) also improved alanine aminotransferase levels alongside other hepatic markers.", "population_specificity": "Patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid.", "effective_dosage": "Not specified for alanine aminotransferase specifically.", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:19.042217+00:00"}
{"study_id": 103115, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the effects of statin treatment on liver function tests, including alanine transaminase (ALT), in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Interventional studies showed significant reductions in ALT, AST, and GGT levels after statin treatment, with percentage mean differences of -35.41%, -31.78%, and -25.57%, respectively, while observational studies found no effect.", "population_specificity": "NAFLD patients with raised ALT, AST, and GGT at baseline.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:19.665053+00:00"}
{"study_id": 103114, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical utility of HBV RNA and HBcrAg biomarkers compared to conventional markers (including alanine aminotransferase, ALT) in differentiating chronic hepatitis B (CHB) phases.", "results_summary": "The study found that HBV RNA and HBcrAg levels were strongly associated with HBV DNA and, to a lesser extent, clinical disease indicators, but had limited additional value in differentiating CHB phases beyond conventional markers. Alanine aminotransferase (ALT) levels were used as part of the conventional markers to categorize CHB phases.", "population_specificity": "Untreated participants in the North American Hepatitis B Research Network Adult Cohort Study (n=1,409) across all CHB phases.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:21.400073+00:00"}
{"study_id": 103113, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine the safety and pharmacodynamic activity of dual macrophage-polarizing therapy (APX005M and cabiralizumab) with or without nivolumab in patients with anti-PD-1/PD-L1-resistant tumors.", "results_summary": "The study demonstrated safety and pharmacodynamic activity of the combination therapy, with the most common adverse events being asymptomatic elevations of lactate dehydrogenase. Optimization of dosing frequency and sequence was suggested for future studies.", "population_specificity": "Patients with advanced melanoma, non-small cell lung cancer (NSCLC), or renal cell carcinoma (RCC) who progressed on anti-PD-1/PD-L1 therapy.", "effective_dosage": "APX005M was dose escalated (0.03, 0.1, or 0.3 mg/kg i.v.) with a fixed dose of cabiralizumab with or without nivolumab every 2 weeks.", "study_duration": "Until disease progression or intolerable toxicity (median follow-up was 21.3 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:21.964403+00:00"}
{"study_id": 103116, "supplement_id": 863, "safety_score": "85", "efficacy_score": 98, "quality_score": 90, "study_goal": "The researchers aimed to assess the hepatic safety, tolerability, and effectiveness of pyronaridine-artesunate, including its impact on alanine aminotransferase (ALT) levels, under real-world conditions in African patients with acute uncomplicated malaria.", "results_summary": "The study found no protocol-defined hepatic events related to pyronaridine-artesunate, even in patients with baseline ALT/AST elevations. Clinical effectiveness at day 28 was high (98.6%), with no adverse effects from comorbidities or malnutrition. Adverse events were mostly mild (e.g., pyrexia, vomiting) and not linked to hepatic toxicity.", "population_specificity": "Adults and children (\u22655 kg) with acute uncomplicated malaria in Cameroon, Democratic Republic of Congo, Gabon, Ivory Coast, and Republic of Congo.", "effective_dosage": "Fixed-dose pyronaridine-artesunate once daily for 3 days, dosed by body weight (tablets for adults/adolescents, pediatric granules for children <20 kg).", "study_duration": "3 days (treatment period); follow-up to day 28.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:23.694984+00:00"}
{"study_id": 103119, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize the toxic and side effects of CDK4/6 inhibitors combined with endocrine therapy in advanced breast cancer, including increased alanine aminotransferase (ALT) levels.", "results_summary": "The study found that CDK4/6 inhibitors combined with endocrine therapy increased the incidence of adverse reactions, including elevated ALT levels, alongside improvements in progression-free survival.", "population_specificity": "Patients with advanced breast cancer (HR+/HER2-).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:25.785898+00:00"}
{"study_id": 103117, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to investigate the effect of dapagliflozin on hepatic and visceral fat contents and related biochemical markers, including alanine aminotransferase, in T2DM patients with NAFLD.", "results_summary": "Dapagliflozin significantly reduced intrahepatic lipid contents, bodyweight, visceral fat, hemoglobin A1c, and alanine aminotransferase levels compared to placebo. No significant changes were observed in adipokines like adiponectin, leptin, or tumor necrosis factor-\u03b1.", "population_specificity": "Non-insulin-dependent type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "10 mg/day", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:25.906299+00:00"}
{"study_id": 103118, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were attempting to determine the efficacy and safety of evinacumab, an angiopoietin-like protein 3 inhibition drug, for hypercholesterolemia treatment, not Alanine.", "results_summary": "The study found that evinacumab significantly reduced LDL-C, triglycerides, and HDL-C without significant adverse effects compared to placebo, but it did not assess Alanine.", "population_specificity": "568 participants in randomized controlled trials evaluating evinacumab.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Not mentioned for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:26.650265+00:00"}
{"study_id": 103120, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of modulated sinusoidal currents electrophoresis and ultraphonophoresis of a phytocomplex (including alanine-related effects) on microcirculation, connective tissue metabolism, and electrolyte balance in knee joint osteoarthritis patients.", "results_summary": "The study found that ultraphonophoresis of the phytocomplex improved alanine aminotransferase and alkaline phosphatase levels, alongside enhancing microcirculation and connective tissue metabolism. Modulated sinusoidal currents electrophoresis also showed benefits but was less effective than ultraphonophoresis.", "population_specificity": "72 patients with knee joint osteoarthritis, divided into five treatment groups.", "effective_dosage": "10% concentration of the phytocomplex in the working composition.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:28.824701+00:00"}
{"study_id": 103121, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of postoperative intensity-modulated radiotherapy (IMRT) for hepatocellular carcinoma (HCC) after narrow-margin hepatectomy, not specifically focusing on Alanine.", "results_summary": "The study found that adjuvant radiotherapy was effective and well-tolerated in HCC patients post narrow-margin hepatectomy, with no marginal recurrence and manageable toxicities, including elevated alanine aminotransferase levels in a small subset of patients.", "population_specificity": "Patients with HCC who underwent narrow-margin hepatectomy (<1 cm pathological margins), aged >18 years, with ECOG performance status 0 or 1.", "effective_dosage": "Not specified (study focused on radiotherapy, not Alanine supplementation).", "study_duration": "Radiotherapy administered within 4-6 weeks post-surgery; median follow-up was 70 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:29.488593+00:00"}
{"study_id": 103122, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare Kawasaki disease shock syndrome (KDSS) with standard Kawasaki disease (KD), focusing on clinical and laboratory differences, including alanine transaminase levels.", "results_summary": "The study found no significant differences in alanine transaminase levels between KDSS and KD patients, but KDSS patients exhibited higher inflammatory markers, lower albumin, and increased complications.", "population_specificity": "Pediatric patients with KDSS or standard KD.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:29.611578+00:00"}
{"study_id": 103123, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 25, "study_goal": "The researchers aimed to summarize and critically appraise early systematic reviews on COVID-19, including clinical symptoms and laboratory findings such as alanine aminotransferase levels.", "results_summary": "The study noted slightly elevated alanine aminotransferase levels in COVID-19 patients but did not focus on its therapeutic effects or safety. No specific conclusions about alanine's efficacy or safety were drawn.", "population_specificity": "COVID-19 patients", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:31.036929+00:00"}
{"study_id": 103124, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine the influence of a soy diet versus placebo on non-alcoholic fatty liver disease, including its effects on alanine aminotransferase levels.", "results_summary": "The study found that a soy diet had no substantial impact on alanine aminotransferase levels (SMD = -0.01; 95% CI = -0.61 to 0.60; P = 0.98). The diet was associated with reduced insulin resistance and malondialdehyde but showed no significant effects on other metabolic markers.", "population_specificity": "Patients with non-alcoholic fatty liver disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:33.446104+00:00"}
{"study_id": 103127, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify deranged metabolic pathways, including alanine, in gestational diabetes mellitus (GDM) and explore potential biomarkers for diagnosis.", "results_summary": "The study found that alanine was among the most commonly deranged amino acids in GDM, suggesting its potential role in the condition's pathophysiology. It also highlighted the possibility of using metabolites like alanine as predictive markers for GDM.", "population_specificity": "Pregnant women with or at risk of gestational diabetes mellitus (GDM).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:35.521987+00:00"}
{"study_id": 103126, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the outcomes of switching from entecavir (ETV) to tenofovir alafenamide (TAF) in chronic hepatitis B patients, including viral suppression and kidney function changes.", "results_summary": "The study found that complete viral suppression (CVS) rates increased from 91.9% at the time of switch to 97.2% at 96 weeks post-switch. Alanine aminotransferase levels did not decrease significantly, and kidney function changes were observed in some patients.", "population_specificity": "Chronic hepatitis B patients (mean age 60.7 years, 60% men, 90.8% Asian) with prior ETV treatment (\u226512 months).", "effective_dosage": "Not specified", "study_duration": "96 weeks post-switch", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:36.786011+00:00"}
{"study_id": 103128, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of Pakistani and American almonds on serum alanine transaminase levels in coronary artery disease patients.", "results_summary": "Dietary almonds (10g/day) significantly reduced serum alanine transaminase levels in intervention groups compared to controls after 12 weeks (p<0.05). The study concluded that a low dose of almonds is effective for liver protection.", "population_specificity": "Coronary artery disease patients at a cardiology clinic in Karachi, Pakistan.", "effective_dosage": "10g/day (soaked overnight, skin removed, consumed before breakfast).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:36.974432+00:00"}
{"study_id": 103131, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates the efficacy and safety of apatinib plus gefitinib in EGFR-mutant NSCLC.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with stage IIIB or IV nonsquamous NSCLC and EGFR exon 19 deletion or exon 21 L858R mutation.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:37.734238+00:00"}
{"study_id": 103129, "supplement_id": 863, "safety_score": "20", "efficacy_score": null, "quality_score": 60, "study_goal": "The researchers aimed to report the first case of severe liver injury associated with zanubrutinib, a Bruton's tyrosine kinase inhibitor, and assess its causality.", "results_summary": "The study found severe hepatocellular injury in a patient after 30 months of zanubrutinib use, with liver biochemistry improving after drug cessation. The causality assessment suggested a probable relationship between zanubrutinib and liver injury.", "population_specificity": "A 56-year-old Caucasian male with relapsed lymphoplasmacytic lymphoma.", "effective_dosage": "Not specified", "study_duration": "30 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:38.534419+00:00"}
{"study_id": 103130, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of berzosertib plus cisplatin in patients with advanced solid tumors.", "results_summary": "The study found that berzosertib plus cisplatin was well tolerated and showed preliminary clinical activity in patients with advanced solid tumors, warranting further evaluation in a Phase 2 setting.", "population_specificity": "Adult patients with advanced solid tumors refractory or resistant to standard of care therapies.", "effective_dosage": "Berzosertib (90-210 mg/m\u00b2) plus cisplatin (day 1) every 3 weeks.", "study_duration": "Every 3 weeks (Q3W) regimen.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:39.012916+00:00"}
{"study_id": 103133, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to identify predictors of severe COVID-19 requiring ICU admission, not specifically to evaluate Alanine.", "results_summary": "The study found elevated alanine aminotransferase levels in ICU-admitted COVID-19 patients compared to non-ICU patients, but did not assess Alanine's effects.", "population_specificity": "Laboratory-confirmed COVID-19 patients admitted to six Saudi hospitals.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:40.218117+00:00"}
{"study_id": 103132, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare serum metabolomic profiles, including alanine levels, between obstructive sleep apnea (OSA) patients and controls to identify potential metabolic alterations.", "results_summary": "The study found significant elevations in median alanine concentrations in OSA patients compared to controls, along with altered overnight dynamics of serum amino acid levels. Alanine levels increased in OSA patients while decreasing in controls, indicating metabolic shifts associated with OSA.", "population_specificity": "31 patients with moderate-to-severe OSA and 32 control individuals.", "effective_dosage": "Not specified", "study_duration": "Overnight blood sampling at three time points (9:00 p.m., 5:00 a.m., and 7:00 a.m.)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:40.570655+00:00"}
{"study_id": 103134, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the prevalence of non-alcoholic fatty liver disease (NAFLD) and its metabolic risk factors in regional Victoria, including the role of serum alanine aminotransferase levels as a marker of liver injury.", "results_summary": "The study found that NAFLD prevalence was high (35.7% age- and sex-standardized), with elevated serum alanine aminotransferase levels (29 U/L vs. 24 U/L) and greater liver stiffness in participants with NAFLD compared to those without.", "population_specificity": "Adults from four towns in the Goulburn Valley of Victoria, Australia (mean age 59.1 years, 56% women).", "effective_dosage": "Not available", "study_duration": "Not applicable (cross-sectional study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:44.480482+00:00"}
{"study_id": 103135, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to analyze the associations of plasma D-dimer levels with clinical variables in COVID-19 patients to understand its role in disease severity and mortality.", "results_summary": "The study found elevated D-dimer levels were significantly associated with disease severity and mortality in COVID-19 patients, identifying 22 clinical variables independently correlated with D-dimer levels.", "population_specificity": "14,862 COVID-19 patients from 42 studies, with no limitations on age, gender, race, or country.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:44.717031+00:00"}
{"study_id": 103136, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the prognostic value of aminotransferases (including alanine aminotransferase) and immunoglobulin G (IgG) during treatment on long-term transplant-free survival in autoimmune hepatitis (AIH).", "results_summary": "Higher AST at 12 months was associated with worse survival, while IgG was not predictive. Normalization of aminotransferases correlated with better long-term survival in AIH patients.", "population_specificity": "301 AIH patients with a median follow-up of 99 months.", "effective_dosage": "Not specified", "study_duration": "Follow-up at 6, 12, 24, and 36 months after therapy initiation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:45.297816+00:00"}
{"study_id": 103137, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the outcomes of chronic hepatitis B virus (HBV) infection in children, focusing on liver disease progression and treatment adherence, with ALT levels as a key biomarker.", "results_summary": "Elevated ALT levels were common (72% of children), with significant flares in 13 cases. Despite many meeting treatment criteria, few received anti-HBV therapy. Major liver-related outcomes (cirrhosis, cancer) were rare.", "population_specificity": "Children with chronic HBV infection in the US and Canada.", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 4.2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:45.632719+00:00"}
{"study_id": 103139, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy of bedtime versus early morning intake of levothyroxine in maintaining euthyroid states in children with hypothyroidism.", "results_summary": "The study found no significant differences in clinical, anthropometric, or biochemical parameters between bedtime and early morning levothyroxine intake, indicating equal efficacy. Bedtime dosing was preferred by a majority of patients in the bedtime group.", "population_specificity": "Children with hypothyroidism who were clinically and biochemically euthyroid.", "effective_dosage": "48.6 \u00b116.9 \u00b5g vs. 49.6 \u00b119.5 \u00b5g (baseline), 48.3 \u00b117.2 \u00b5g vs. 51.9 \u00b118.0 \u00b5g (endpoint)", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:48.244407+00:00"}
{"study_id": 103140, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to analyze HBV genome diversity in relation to TDF treatment and HBeAg seroconversion, with a focus on viral diversity and its association with alanine aminotransferase (ALT) levels.", "results_summary": "The study found higher viral diversity in the X region at baseline, linked to higher ALT levels, and observed a reduction in viral diversity after TDF treatment. For placebo patients who seroconverted, viral diversity dropped alongside reduced serum HBV DNA.", "population_specificity": "Adolescents with chronic hepatitis B (CHB)", "effective_dosage": "Not specified", "study_duration": "192 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:48.375426+00:00"}
{"study_id": 103138, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of combined lipid-lowering therapy (atorvastatin and ezetimibe) versus intensive statin therapy on LDL-C variability, inflammatory markers, and cardiovascular adverse events in ACS patients, including monitoring ALT levels as a safety parameter.", "results_summary": "The study found that combined therapy improved lipid profiles, inflammatory markers (MMP-9, hsCRP), and ALT levels more effectively than intensive statin therapy, with a lower incidence of cardiovascular adverse events (6.59% vs. 11.96%). Safety profiles were comparable between groups.", "population_specificity": "200 patients with acute coronary syndrome (ACS).", "effective_dosage": "10 mg/day atorvastatin + 10 mg/day ezetimibe (observation group); 40 mg/day atorvastatin (control group).", "study_duration": "24 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:48.567987+00:00"}
{"study_id": 103141, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 25, "quality_score": 85, "study_goal": "The researchers aimed to determine the long-term incidences and baseline predictors of functional cure (HBsAg seroclearance) in chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate, focusing on factors like alanine aminotransferase levels.", "results_summary": "The study found that HBsAg seroclearance was rare (0.22% annual rate) and associated with low-level viremia, elevated alanine aminotransferase (>200 U/L), serum bilirubin, and fatty liver. Alanine aminotransferase flare was a significant predictor of functional cure.", "population_specificity": "Treatment-naive chronic hepatitis B patients without baseline cancer (median age 50, 69.05% male).", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 5.16 years (26,614.47 person-years).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:50.687878+00:00"}
{"study_id": 103144, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on comparing the efficacy and safety of ipilimumab plus anti-PD-1 versus ipilimumab monotherapy in patients resistant to anti-PD-(L)1 therapy for metastatic melanoma.", "results_summary": "The study does not report any findings related to Alanine.", "population_specificity": "Patients with metastatic melanoma resistant to anti-PD-(L)1 therapy.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:51.456148+00:00"}
{"study_id": 103143, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify indicators of severe COVID-19 and observe the natural course of the disease without clinical intervention, including monitoring changes in alanine aminotransferase levels.", "results_summary": "The study found that alanine aminotransferase levels gradually increased with delayed hospitalization in COVID-19 patients, peaking around 10-14 days after onset, but did not specifically evaluate alanine's therapeutic effects.", "population_specificity": "158 COVID-19 patients from two hospitals.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:51.855358+00:00"}
{"study_id": 103146, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine if dried plum consumption reduces cardiovascular disease risk factors, such as lipid profiles, oxidative stress, antioxidant capacity, and inflammation, in postmenopausal women.", "results_summary": "The study found that consuming 100 g/day of dried plum reduced total cholesterol (TC) in postmenopausal women after 6 months, suggesting potential cardiovascular benefits.", "population_specificity": "Postmenopausal women", "effective_dosage": "0, 50, or 100 g/day", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:53.025502+00:00"}
{"study_id": 103149, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers investigated the effects of saffron supplementation on metabolic biomarkers, mood, sleep quality, and overall quality of life in overweight/obese patients with type 2 diabetes.", "results_summary": "Saffron supplementation significantly reduced fasting plasma glucose, triglycerides, insulin, and liver enzymes (AST and ALT), while also improving depression scores, sleep quality, and overall quality of life.", "population_specificity": "Overweight/obese patients with type 2 diabetes (n=70).", "effective_dosage": "100 mg/day", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:56.117145+00:00"}
{"study_id": 103145, "supplement_id": 863, "safety_score": "85", "efficacy_score": 95, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy, safety, and tolerability of pyronaridine-artesunate (PA) in asymptomatic Plasmodium falciparum-infected individuals, including full (3-day) and incomplete (2-day, 1-day) treatment regimens.", "results_summary": "PA demonstrated high efficacy (100% PCR-adjusted APR at day 28 for 3-day and 2-day regimens, 96.8% for 1-day) and good tolerability, with similar adverse event frequencies across regimens and mostly mild (grade 1 or 2) severity. Transient increases in alanine aminotransferase/aspartate aminotransferase were observed in 2% of participants.", "population_specificity": "Asymptomatic Plasmodium falciparum-infected individuals in The Gambia and Zambia.", "effective_dosage": "180:60 mg PA, dosed according to bodyweight, administered as 3-day, 2-day, or 1-day regimens.", "study_duration": "3-day, 2-day, or 1-day treatment regimens, with follow-up until day 63.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:56.126938+00:00"}
{"study_id": 103147, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the impact of non-alcoholic fatty liver disease (NAFLD) on Health-Related Quality of Life (HRQL) in a Chinese population, with a focus on identifying risk factors including alanine transaminase (ALT) levels.", "results_summary": "The study found that ALT levels were an independent risk factor for impaired HRQL in NAFLD patients, alongside BMI, triglyceride levels, disease severity, and cardiovascular disease. ALT influenced several HRQL domains, indicating its role in the overall health status of these patients.", "population_specificity": "Chinese patients with NAFLD (n=5181, mean age 43.8 \u00b1 13.3 years, 65.8% male).", "effective_dosage": "Not specified", "study_duration": "Not specified (cross-sectional study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:57.151074+00:00"}
{"study_id": 103148, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether tenofovir alafenamide (TAF) could replace tenofovir disoproxil fumarate (TDF) in patients with drug-resistant hepatitis B virus (HBV) while assessing safety and efficacy.", "results_summary": "TAF showed non-inferior efficacy to TDF in maintaining HBV DNA suppression, with improved bone and renal safety but increased body weight and cholesterol levels. Changes in alanine aminotransferase and bone mineral density were statistically significant in favor of TAF.", "population_specificity": "Patients with HBV resistant to multiple drugs (lamivudine, entecavir, and/or adefovir) under TDF monotherapy for \u226596 weeks.", "effective_dosage": "Not specified in the abstract.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:57.918948+00:00"}
{"study_id": 103150, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to statistically summarize routine laboratory biomarker measurements, including alanine aminotransferase, in COVID-19-positive and -negative patients to inform future diagnostic work.", "results_summary": "The study found that alanine aminotransferase levels were elevated in COVID-19-positive patients compared to COVID-19-negative patients, but it did not assess alanine's efficacy or safety as a supplement.", "population_specificity": "Patients diagnosed with COVID-19 (positive and negative groups)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:58.770792+00:00"}
{"study_id": 103151, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the safety and tolerability of savolitinib, including its effects on alanine aminotransferase levels, in Japanese patients with advanced solid malignancies.", "results_summary": "The study found that savolitinib monotherapy at 600 mg resulted in dose-limiting toxicities, including grade 3 and 4 alanine aminotransferase increases, while 400 mg was deemed the maximum tolerated dose with an acceptable safety profile. Combination therapy with osimertinib also showed dose-dependent toxicities, with 400 mg being the safest dose.", "population_specificity": "Japanese adult patients with advanced solid malignancies or EGFR mutation-positive NSCLC.", "effective_dosage": "400 mg once daily (monotherapy and combination), escalating to 600 mg.", "study_duration": "Not specified in the abstract.", "interactions": "Combination therapy with osimertinib was noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:00.693795+00:00"}
{"study_id": 103152, "supplement_id": 863, "safety_score": "40", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of LY3381916 (an IDO1 inhibitor) alone and in combination with a PD-L1 inhibitor in patients with advanced solid tumors.", "results_summary": "The study found dose-limiting toxicities, including liver toxicity and immune-related hepatitis, particularly in combination therapy. The combination showed maximal IDO1 inhibition and increased CD8 T cells in tumors, but clinical activity was limited, with best response being stable disease.", "population_specificity": "Patients with advanced solid tumors, including triple-negative breast cancer and non-small cell lung cancer.", "effective_dosage": "60-600 mg once daily (qd), 240 mg twice daily (monotherapy); 240 mg qd in combination with PD-L1 inhibitor (700 mg every 2 weeks).", "study_duration": "Not specified in the abstract.", "interactions": "Interaction with PD-L1 inhibitor (LY3300054) noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:01.581158+00:00"}
{"study_id": 103153, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and antitumor activity of MORAb-202, an antibody-drug conjugate, in patients with FR\u03b1-positive solid tumors.", "results_summary": "MORAb-202 showed promising antitumor activity, with complete response in one patient, partial response in nine, and stable disease in eight. Adverse events were common, including leukopenia, neutropenia, and interstitial lung disease, but the treatment was generally well-tolerated.", "population_specificity": "Patients \u226520 years with FR\u03b1-positive solid tumors who failed standard therapy.", "effective_dosage": "0.3 to 1.2 mg/kg intravenously once every three weeks.", "study_duration": "From November 28, 2017, to June 4, 2019 (approximately 1.5 years).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:02.201208+00:00"}
{"study_id": 103154, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were attempting to determine the role of IL-35+B cells in chronic HBV infection, not Alanine.", "results_summary": "The study did not investigate Alanine; it focused on IL-35+B cells in HBV infection.", "population_specificity": "Patients with persistent hepatitis B virus (HBV) infection.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:02.484240+00:00"}
{"study_id": 103156, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to examine the effect of purslane hydroalcoholic extract on liver enzymes, particularly alanine aminotransferase (ALT), in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that purslane extract significantly reduced ALT, AST, GGT, fasting blood glucose, insulin resistance, triglycerides, and LDL-C in the treatment group, but no significant changes were observed in liver steatosis grade, insulin, liver enzymes, lipid profile, or glycemic indices between the two groups by the end of the study.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD)", "effective_dosage": "300 mg/day", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:05.216217+00:00"}
{"study_id": 103155, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of peginterferon alpha (peg-IFN-\u03b1) monotherapy in inactive hepatitis B virus (HBV) carriers, focusing on HBsAg clearance and seroconversion rates.", "results_summary": "Peg-IFN-\u03b1 monotherapy significantly increased HBsAg clearance (47.9%) and seroconversion (36.6%) rates compared to the control group (1.9% and 0.6%, respectively). The therapy was well tolerated, with only five participants discontinuing due to adverse events.", "population_specificity": "Inactive hepatitis B virus (HBV) carriers in China.", "effective_dosage": "Not specified (48-week treatment duration).", "study_duration": "48 weeks of treatment, followed up to 72 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:05.243755+00:00"}
{"study_id": 103158, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify severity subgroups among COVID-19 patients using clinical and laboratory data, including alanine transaminase (ALT) levels, but not to evaluate Alanine as a supplement.", "results_summary": "The study found that ALT levels, along with other markers, helped distinguish severe COVID-19 cases (cluster 1) from less severe cases (clusters 2 and 3). Higher ALT levels were associated with worse outcomes.", "population_specificity": "853 COVID-19 patients assessed in emergency departments in Madrid, Spain.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:05.985110+00:00"}
{"study_id": 103157, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "To assess the safety and efficacy of olipudase alfa enzyme replacement therapy for non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in children.", "results_summary": "Olipudase alfa was generally well-tolerated, with most adverse events being mild or moderate. Significant improvements in splenomegaly, hepatomegaly, and lung function were observed.", "population_specificity": "Children with chronic ASMD, including adolescents (12-17 years), children (6-11 years), and infants/early children (1-5 years).", "effective_dosage": "3 mg/kg administered intravenously every 2 weeks.", "study_duration": "64 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:06.673353+00:00"}
{"study_id": 103159, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the predictive value of histological normalization for successful immunosuppressive therapy withdrawal in autoimmune hepatitis (AIH) patients with biochemical remission, including normal serum alanine aminotransferase (ALT) levels.", "results_summary": "The study found that two-thirds of AIH patients with histological normalization after at least 2 years of biochemical remission achieved treatment-free remission, while one-third required reinstitution of therapy without clinical disease progression. Persistent histological inflammation was associated with higher ALT and AST levels.", "population_specificity": "Non-cirrhotic patients with autoimmune hepatitis in complete biochemical remission (normal ALT, AST, and IgG) for at least 2 years.", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 62 months (range: 13-75 months) after therapy withdrawal", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:09.672036+00:00"}
{"study_id": 103160, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of metformin with and without curcumin nanomicelles on biochemical and hormonal parameters, including alanine aminotransferase (ALT), in women with PCOS.", "results_summary": "The study found that ALT levels were evaluated but did not report significant changes specific to ALT. The primary focus was on improvements in insulin resistance and lipid profiles with curcumin and metformin.", "population_specificity": "100 women with PCOS diagnosed according to the Rotterdam criteria.", "effective_dosage": "500 mg metformin three times daily (group 1); 80 mg/day curcumin nanomicelle plus 500 mg metformin three times daily (group 2).", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:09.903464+00:00"}
{"study_id": 103162, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate and compare the therapeutic effects of various hypoglycemic agents, including their impact on alanine aminotransferase (ALT) levels, in NAFLD patients with or without diabetes.", "results_summary": "Thiazolidinediones, particularly pioglitazone, showed significant reductions in ALT and AST levels but were associated with weight gain. GLP1 RAs and metformin also demonstrated beneficial effects on ALT and AST levels, though with less risk of weight gain.", "population_specificity": "NAFLD patients with or without diabetes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:10.956143+00:00"}
{"study_id": 103161, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the safety and effectiveness of a carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for newly diagnosed multiple myeloma, not specifically focused on Alanine.", "results_summary": "The study found that the combination therapy achieved high rates of minimal residual disease negativity (71%) and high progression-free survival rates (98% at 1 year). Increased alanine aminotransferase levels were noted as a grade 3 or 4 adverse event in 2 patients (4%).", "population_specificity": "Patients with newly diagnosed multiple myeloma (median age 59 years; 61% female; 49% high-risk).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Eight 28-day cycles (approximately 8 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:12.711535+00:00"}
{"study_id": 103166, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare hepatic fibrosis markers and hepatic function indices, including alanine aminotransferase (ALT), in patients with liver cirrhosis and hepatoma of varying etiology.", "results_summary": "The study found no correlation between ALT and hepatic fibrosis markers in liver cirrhosis caused by hepatitis B, but AST (a related enzyme) showed positive correlations with some fibrosis markers. ALT was not significantly correlated with fibrosis markers in hepatoma caused by hepatitis B.", "population_specificity": "108 patients with liver cirrhosis and hepatoma, plus 20 healthy controls.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:14.303604+00:00"}
{"study_id": 103163, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the association between changes in liver stiffness measurement (LSM) and histological outcomes, including alanine aminotransferase normalization, in patients with chronic hepatitis B undergoing entecavir-based therapy.", "results_summary": "A \u226530% decrease in LSM was associated with regression of fibrosis, significant histological response, and alanine aminotransferase normalization. However, changes in LSM were deemed unreliable for estimating fibrosis regression during treatment.", "population_specificity": "Treatment-naive patients with chronic hepatitis B (n=727).", "effective_dosage": "Not specified (entecavir-based therapy).", "study_duration": "72 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:14.420480+00:00"}
{"study_id": 103165, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of benznidazole monotherapy regimens and combinations with fosravuconazole for treating Chagas disease, not specifically Alanine.", "results_summary": "The study found that benznidazole, in various dosages and durations, induced effective antiparasitic response and was well tolerated, but did not specifically assess Alanine.", "population_specificity": "Adults aged 18-50 years with chronic indeterminate Chagas disease in Bolivia.", "effective_dosage": "Not applicable (study focused on benznidazole and fosravuconazole).", "study_duration": "Varied by treatment group (2 weeks to 8 weeks).", "interactions": "None mentioned (study focused on benznidazole and fosravuconazole).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:14.594610+00:00"}
{"study_id": 103164, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to describe the clinical characteristics, treatment, and outcomes of patients with macrophage activation syndrome (MAS) and thrombotic microangiopathy (TMA), including the role of alanine aminotransferase levels as a marker of disease severity.", "results_summary": "The study found that patients with coexistent MAS and TMA had higher levels of alanine aminotransferase, indicating more severe liver involvement, along with other markers of disease severity such as anemia, thrombocytopenia, and multiorgan failure. Alanine aminotransferase was one of several laboratory markers used to assess disease severity but was not the primary focus of the study.", "population_specificity": "Pediatric patients with rheumatic diseases, including systemic juvenile idiopathic arthritis (sJIA), systemic lupus erythematosus, juvenile dermatomyositis, mixed connective tissue disease, and undifferentiated connective tissue disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:15.094117+00:00"}
{"study_id": 103167, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of a combined hepatotonic agent (biphenyl dimethyl dicarboxylate/ursodeoxycholic acid) in reducing ALT levels in patients with chronic liver disease related to metabolic syndrome.", "results_summary": "The intervention group showed significant ALT normalization (50%) compared to the placebo group (6%), but no improvements were observed in hepatic steatosis, fibrosis, or quality of life measures.", "population_specificity": "Adults with chronic hepatitis and one or more components of metabolic syndrome.", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:17.502100+00:00"}
{"study_id": 103168, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the effect of acupoint therapy on liver function and lipid metabolism in patients with nonalcoholic fatty liver disease (NAFLD), including its impact on alanine aminotransferase (ALT) levels.", "results_summary": "Acupoint therapy significantly improved ALT and AST levels, reduced triglyceride (TG), total cholesterol (TC), and low-density lipoprotein (LDL) levels, and increased high-density lipoprotein (HDL) levels in NAFLD patients.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD) (n=1320 across 16 RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:18.493500+00:00"}
{"study_id": 103169, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of saroglitazar in improving ALT levels, liver fat content, insulin resistance, and atherogenic dyslipidemia in patients with NAFLD/NASH.", "results_summary": "Saroglitazar 4 mg significantly improved ALT, liver fat content, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. The study demonstrated clinically meaningful outcomes in these metabolic parameters.", "population_specificity": "Patients with NAFLD/NASH, ALT \u2265 50 U/L, and BMI \u2265 25 kg/m\u00b2.", "effective_dosage": "4 mg (frequency not specified)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:19.110667+00:00"}
{"study_id": 103171, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to analyze clinical characteristics of aortic aneurysm (AA) patients, including differences in laboratory variables like alanine aminotransferase, to explore implications for management.", "results_summary": "Higher levels of alanine aminotransferase were observed in nonsurvivors of abdominal aortic aneurysm (AAA), but the study did not evaluate alanine's therapeutic effects or safety.", "population_specificity": "Patients with aortic aneurysm (AAA and TAA) from the MIMIC-III database.", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:20.785894+00:00"}
{"study_id": 103172, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to identify risk factors, including elevated alanine aminotransferase (ALT), associated with COVID-19 progression and mortality.", "results_summary": "Increased ALT levels were significantly more frequent in severe COVID-19 cases compared to non-severe cases, suggesting a potential association with disease severity. However, the study did not establish causality or therapeutic implications for alanine itself.", "population_specificity": "344,431 participants from 34 studies, primarily COVID-19 patients with varying disease severity.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:21.927582+00:00"}
{"study_id": 103173, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the association of early-pregnancy biomarkers, including alanine transaminase, with the risk of gestational diabetes mellitus (GDM).", "results_summary": "The study found that alanine transaminase was consistently and significantly associated with GDM risk, irrespective of confounding adjustments (p < 0.001). However, the abstract does not specify whether higher or lower levels of alanine transaminase were linked to increased GDM risk.", "population_specificity": "187,432 gestational women without pre-pregnancy diabetes, including 49,611 with GDM and 137,821 without GDM.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:22.949833+00:00"}
{"study_id": 103175, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were examining the association between cardiac involvement in Latin American children with multisystem SARS COV2 and elevated alanine aminotransferase (ALT) levels, among other factors.", "results_summary": "The study found that children with cardiac involvement had significantly higher ALT levels (33% vs 12%, p = 0.02) compared to those without cardiac involvement, suggesting a potential biomarker relationship. Elevated ALT, along with other abnormal labs, had high sensitivity and negative predictive value for ICU interventions.", "population_specificity": "Latin American children (0-18 years old) with multisystem SARS COV2, from 10 countries.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:24.122986+00:00"}
{"study_id": 103174, "supplement_id": 863, "safety_score": "65", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of E7777 (a recombinant fusion protein) in patients with relapsed or refractory PTCL and CTCL.", "results_summary": "The study found an objective response rate of 36% (41% in PTCL, 31% in CTCL), with a median progression-free survival of 3.1 months. Common adverse events included increased AST/ALT, hypoalbuminemia, lymphopenia, and pyrexia, but the safety profile was deemed manageable.", "population_specificity": "Japanese patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).", "effective_dosage": "9 \u00b5g/kg/day", "study_duration": "Not specified in the abstract", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:24.184564+00:00"}
{"study_id": 103176, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize gastrointestinal manifestations and disease course in COVID-19 patients, including liver damage markers like alanine aminotransferase (ALT).", "results_summary": "Elevated ALT was observed in 62.7% of COVID-19 patients, but these patients did not present a more severe disease course. Digestive symptoms were associated with less severe disease.", "population_specificity": "COVID-19 patients admitted to a European center between March and April 2020 (median age 71 years; 56.2% male).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:25.483157+00:00"}
{"study_id": 103177, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to establish region-specific reference intervals for laboratory parameters, including alanine transferase (ALT), in a healthy Kenyan population.", "results_summary": "The study found that ALT reference intervals were higher in males (8.8-45.3 U/L) compared to females (7.5-36.8 U/L), with significant variation (SDR > 0.3) compared to prior studies in Kenya and the US.", "population_specificity": "Healthy males and females aged 18-35 years without HIV in Kombewa, Kenya.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:26.480983+00:00"}
{"study_id": 103179, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the efficacy and safety of furmonertinib, not Alanine, in patients with EGFR T790M mutated advanced non-small-cell lung cancer (NSCLC).", "results_summary": "The study found furmonertinib had promising efficacy (74% objective response rate) and an acceptable safety profile, but it did not evaluate Alanine.", "population_specificity": "Patients with locally advanced or metastatic NSCLC with EGFR T790M mutations.", "effective_dosage": "Not applicable (study focused on furmonertinib, not Alanine).", "study_duration": "Median follow-up was 9.6 months (range 0.7-19.4).", "interactions": "None mentioned (study did not assess Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:27.735479+00:00"}
{"study_id": 103181, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of 6 months of UDCA treatment on hepatic function, lipid profile, hepatic steatosis and fibrosis, atherogenesis, and ASCVD risk in patients with NAFLD, as well as the impact of weight reduction on these parameters.", "results_summary": "UDCA significantly reduced ALT levels, improved lipid profile and hepatic steatosis independent of weight loss, and had a positive effect on CIMT and 10-year ASCVD risk in women after 6 months of treatment. The greatest improvements in liver enzymes occurred within the first 3 months.", "population_specificity": "174 patients with ultrasound-diagnosed NAFLD, both men and women.", "effective_dosage": "15 mg/kg/d UDCA.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:31.295708+00:00"}
{"study_id": 103182, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the predictive effect of preoperative inflammatory factors, including the AST-ALT ratio (which involves alanine aminotransaminase), on overall survival in patients with gastric adenocarcinoma.", "results_summary": "The study found that a higher AST-ALT ratio (>1.21) was significantly associated with shorter overall survival in gastric adenocarcinoma patients, suggesting its potential as a prognostic marker. Other inflammatory factors like NLR and PLR did not show significant associations with survival outcomes.", "population_specificity": "Patients diagnosed with gastric adenocarcinoma (207 participants).", "effective_dosage": "Not specified", "study_duration": "Retrospective data collected between January 2011 and October 2020.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:31.304693+00:00"}
{"study_id": 103180, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the long-term outcomes of chronic hepatitis B (CHB) patients who received antiviral therapy versus those who received only liver protection and anti-inflammatory treatment.", "results_summary": "The study found that antiviral therapy led to higher rates of undetectable HBV DNA and HBeAg seroconversion compared to non-antiviral treatment. However, the cumulative incidence of hepatocellular carcinoma (HCC) was not significantly different between the two groups for CHB patients, though antiviral therapy showed a lower HCC incidence in cirrhosis patients.", "population_specificity": "Patients with chronic hepatitis B (CHB) and hepatitis B cirrhosis in China.", "effective_dosage": "Not specified", "study_duration": "Median follow-up times were 10 years for CHB and 7 years for cirrhosis in the non-antiviral group, and 8 years for CHB and 7 years for cirrhosis in the antiviral group.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:31.622145+00:00"}
{"study_id": 103184, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the safety, tolerability, and efficacy of combining evofosfamide (a hypoxia-alleviating prodrug) with ipilimumab (an immune checkpoint inhibitor) in immunologically \"cold\" and \"hot/warm\" metastatic cancers resistant to immunotherapy.", "results_summary": "The study found no new or unexpected safety signals from the combination of evofosfamide and ipilimumab, and noted evidence of therapeutic activity.", "population_specificity": "Patients with immunologically \"cold\" cancers and \"hot/warm\" metastatic cancers resistant to immunotherapy, including castration-resistant prostate cancer.", "effective_dosage": "Evofosfamide (400-640 mg/m\u00b2)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:32.965938+00:00"}
{"study_id": 103185, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate clinical and immunological responses to SARS-CoV-2 infection, including the role of alanine aminotransferase (ALT) as a marker of liver damage, across different age and sex groups.", "results_summary": "The study found that old males and females had higher plasma ALT concentrations compared to young patients, and males generally had higher ALT levels than females, indicating age- and sex-related differences in liver damage during COVID-19.", "population_specificity": "681 COVID-19 patients and 369 normal controls, categorized by age (young and old) and sex (male and female).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:33.978578+00:00"}
{"study_id": 103186, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were attempting to determine the impact of remdesivir on renal and liver function in Covid-19 patients, not Alanine.", "results_summary": "The study found that 20% of patients met exclusion criteria for remdesivir due to poor renal or liver function, and 11% experienced a significant decrease in kidney function post-treatment. No findings related to Alanine were reported.", "population_specificity": "Covid-19 patients who received remdesivir (n=103).", "effective_dosage": "Not mentioned (study focused on remdesivir, not Alanine).", "study_duration": "15 days after treatment initiation.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:34.342019+00:00"}
{"study_id": 103183, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of a combination of pentoxifylline (PTX) and vitamin E (VE) compared to VE alone in reducing alanine aminotransferase (ALT) levels and improving fibrosis in patients with non-alcoholic steatohepatitis (NASH).", "results_summary": "Both treatment groups showed similar reductions in ALT levels, but the PTX and VE combination (PTVE) group demonstrated greater reductions in fasting insulin, HOMA-IR, and TNF\u03b1 levels, as well as significant fibrosis regression compared to the VE-only group.", "population_specificity": "Patients with histologically proven NASH.", "effective_dosage": "PTX 400 mg thrice daily and VE 400 IU twice daily (PTVE group); VE alone (400 IU twice daily, VE group).", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:34.396256+00:00"}
{"study_id": 103187, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 86, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of various agents, including metabolic target agents and natural plant drugs, on NAFLD, with a focus on liver pathology improvement and metabolic indicators such as alanine aminotransferase (ALT) levels.", "results_summary": "Obeticholic acid and elafibranor showed relative advantages in reducing ALT levels, with obeticholic acid also reducing AST levels. However, obeticholic acid had adverse effects on lipid metabolism, increasing LDL-C and decreasing HDL-C levels.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:36.470726+00:00"}
{"study_id": 103190, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate histological and clinical outcomes in HBV-HIV co-infected patients on combination antiretroviral therapy (cART).", "results_summary": "The study found that clinical outcomes and worsening histological disease were uncommon in HBV-HIV co-infected adults on cART with virological suppression.", "population_specificity": "Adult patients co-infected with HBV-HIV from eight North American sites (n=139, median age 49 years, 91% male, 51% non-Hispanic Black).", "effective_dosage": "Not mentioned", "study_duration": "Follow-up for \u2264192 weeks (paired liver biopsies at entry and \u22653 years).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:39.314165+00:00"}
{"study_id": 103191, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the rate and risk factors for persistent elevated alanine aminotransferase (ALT) levels in chronic hepatitis C patients with advanced fibrosis after achieving sustained virological response (SVR) from direct-acting antiviral (DAA) treatment.", "results_summary": "The study found that 9.8% of patients had persistent liver inflammation (elevated ALT levels) after SVR, which was associated with baseline liver function impairment, steatosis, and other factors. Multivariate analysis identified baseline serum total bilirubin, international normalized ratio, ALT levels, and steatosis as independent predictors of persistent liver inflammation.", "population_specificity": "Chronic hepatitis C patients with advanced fibrosis (46.4% cirrhosis) who achieved SVR after DAA treatment.", "effective_dosage": "Not specified", "study_duration": "Follow-up until SVR12 (12 weeks post-treatment)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:41.264586+00:00"}
{"study_id": 103188, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the performance of shear-wave elastography (SWE) in detecting liver fibrosis in children with cystic fibrosis, using alanine aminotransferase (ALT) as one of the biomarkers.", "results_summary": "The study found that 6-MHz point SWE correlated with MR elastography (r=0.52) and identified specific SWE thresholds (1.45 m/s and 1.84 m/s) for distinguishing normal from abnormal liver stiffness and mild-moderate from severe fibrosis. Elevated ALT levels were associated with higher SWE values, indicating potential liver fibrosis.", "population_specificity": "Children and adolescents with cystic fibrosis (94 participants, 178 SWE exams).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:41.306505+00:00"}
{"study_id": 103192, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the association between baseline plasma alanine aminotransferase levels and mortality in patients with Lassa fever.", "results_summary": "Elevated plasma alanine aminotransferase (\u22653 times the upper limit of normal) was independently associated with higher mortality (adjusted odds ratio 4.96, 95% CI 1.69-14.60). The study did not evaluate alanine as a supplement but as a biomarker of liver injury.", "population_specificity": "Patients hospitalized with confirmed Lassa fever in Nigeria (510 participants, including adults and children).", "effective_dosage": "Not applicable (alanine was measured as a biomarker, not administered).", "study_duration": "Not applicable (alanine levels were assessed at baseline).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:41.799721+00:00"}
{"study_id": 103194, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of saffron supplementation on liver function tests, including alanine aminotransferase (ALT), in adults.", "results_summary": "The study found that saffron supplementation had no significant effect on ALT levels or other liver function tests (AST, ALP) compared to placebo. The results were statistically non-significant and showed minimal clinical relevance.", "population_specificity": "Adults (608 participants across 12 trials)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:42.477006+00:00"}
{"study_id": 103193, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to assess hemodynamic and metabolic parameters, including alanine aminotransferase (ALT), in relation to liver and renal function during organ transplant procedures.", "results_summary": "The study found no significant correlation between alanine aminotransferase (ALT) and extravascular lung water or intrathoracic blood volume index, but base excess was correlated with ALT.", "population_specificity": "11 patients with advanced pulse indicator continuous cardiac output monitoring during organ transplant procedures.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:42.672847+00:00"}
{"study_id": 103195, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate health and safety issues related to metal exposure in additive manufacturing (AM) operators, including the role of alanine transaminase as a hepatic marker.", "results_summary": "The study found that AM operators had higher levels of hepatic markers, including alanine transaminase, compared to controls, suggesting potential liver-related effects from metal exposure. Blood cobalt and antioxidant/inflammatory markers were also elevated in AM operators.", "population_specificity": "AM operators, welders, and office workers as controls.", "effective_dosage": "Not available", "study_duration": "Two consecutive years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:43.414744+00:00"}
{"study_id": 103196, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the potential benefits of Nigella sativa (NS) supplementation, including its effects on alanine transaminase (ALT) levels, in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "NS supplementation improved ALT, AST, FBS, HDL, hs-CRP levels, and reduced the severity of NAFLD, but had no effect on TC, LDL, TG, insulin, or TNF-\u03b1 levels.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:44.244089+00:00"}
{"study_id": 103197, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate risk factors for liver injury in severe COVID-19 patients and identify measures to reduce mortality risk, not specifically focusing on Alanine.", "results_summary": "The study found that liver injury in COVID-19 patients was more common in those aged \u2265 65 years, females, or those with comorbidities, decreased lymphocyte count, or elevated D-dimer or serum ferritin. It recommended monitoring liver enzymes and being cautious with hepatotoxic drugs.", "population_specificity": "440 consecutive severe or critical COVID-19 patients at Tongji Hospital, Wuhan, China.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:47.911831+00:00"}
{"study_id": 103199, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to quantify the impact of COVID-19 on the digestive system of children, including changes in liver function such as increased alanine aminotransferase (ALT).", "results_summary": "The study found that the pooled incidence of increased ALT in children with COVID-19 was 8% (95% CI: 5-15), indicating liver function changes. The recovery rate was high (97%), and the death rate was low (1%).", "population_specificity": "Children with COVID-19 exhibiting digestive system involvement.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:49.598591+00:00"}
{"study_id": 103202, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of metformin treatment on aminotransferase levels (including ALT), metabolic parameters, and body mass index in NAFLD patients.", "results_summary": "Metformin effectively reduced serum fasting glucose, insulin levels, and the HOMA-IR index at 6 months, and ALT and HOMA-IR at 12 months, though its effects on lipid metabolism and BMI were similar to controls.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "6-month and 12-month follow-ups", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:51.094706+00:00"}
{"study_id": 103198, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess the effect of FDA-approved endoscopic bariatric and metabolic therapies (EBMTs) on nonalcoholic fatty liver disease (NAFLD), including changes in liver fibrosis and other NAFLD surrogates such as alanine aminotransferase levels.", "results_summary": "The study found significant improvements in liver fibrosis (SMD: 0.7), alanine aminotransferase levels (-9.0 U/L), hepatic steatosis (SMD: -1.0), and histologic NAFLD activity score (-2.50) following EBMTs. Other metabolic parameters, including insulin resistance and waist circumference, also improved significantly.", "population_specificity": "863 patients with obesity and NAFLD.", "effective_dosage": "Not specified for Alanine.", "study_duration": "6-month follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:51.507580+00:00"}
{"study_id": 103201, "supplement_id": 863, "safety_score": "80", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of antiviral therapy (including alanine aminotransferase monitoring) in children and adolescents with immune-tolerant chronic hepatitis B.", "results_summary": "The antiviral regimen showed acceptable tolerability but was ineffective, with only 1 of 26 treated patients achieving HBsAg loss. No serious treatment-related adverse events were reported.", "population_specificity": "Children and adolescents aged 3 to <18 years with immune-tolerant chronic hepatitis B.", "effective_dosage": "Not specified for alanine aminotransferase (monitored, not dosed). Antiviral therapy included entecavir or lamivudine plus peginterferon alfa-2a.", "study_duration": "56 weeks of antiviral therapy plus 24 weeks post-treatment follow-up.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:52.479851+00:00"}
{"study_id": 103200, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of dacomitinib versus gefitinib as first-line therapy for EGFR mutation-positive advanced NSCLC in Asian patients.", "results_summary": "The study found that dacomitinib significantly prolonged progression-free survival (PFS) and improved overall survival (OS) compared to gefitinib in Asian patients with EGFR mutation-positive advanced NSCLC. Common adverse events included diarrhea, paronychia, dermatitis acneiform, and stomatitis with dacomitinib, and diarrhea and increased alanine aminotransferase with gefitinib.", "population_specificity": "Asian patients with newly diagnosed advanced EGFR mutation-positive NSCLC.", "effective_dosage": "Dacomitinib 45 mg/day (with stepwise reduction to 30 and 15 mg/day) or gefitinib 250 mg/day.", "study_duration": "Median follow-up was 37.7 months for dacomitinib and 29.1 months for gefitinib.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:53.527572+00:00"}
{"study_id": 103203, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), including the frequency and clinical significance of new-onset liver injury (alanine aminotransferase > 2 \u00d7 the upper limit of normal) during COVID-19.", "results_summary": "The study found that new-onset liver injury occurred in 37.1% of AIH patients with COVID-19, with antiviral use associated with higher liver injury risk and continued immunosuppression linked to lower risk. Severe COVID-19 outcomes and mortality rates were similar between AIH and non-AIH chronic liver disease patients, with cirrhosis being the strongest predictor of severe COVID-19 in AIH patients.", "population_specificity": "Patients with autoimmune hepatitis (AIH) and COVID-19 (80% female, median age 49 years) from 34 centers in Europe and the Americas.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Antivirals were associated with increased liver injury risk, while continued immunosuppression reduced liver injury risk.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:53.968721+00:00"}
{"study_id": 103204, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the serological, virological, and histological effects of multiple-dose ARC-520 (in combination with entecavir) in chronic HBV patients, including the impact on viral antigens and HBV RNA.", "results_summary": "The study found profound reductions in viral antigens (HBsAg, HBeAg) and HBV RNA in HBeAg-positive patients, with some achieving seroconversion. HBeAg-negative patients also showed modest HBsAg reductions, with one achieving seroconversion and sustained clearance.", "population_specificity": "Chronic hepatitis B virus (HBV) patients (8 total, 3 HBeAg-positive and 5 HBeAg-negative).", "effective_dosage": "4-9 doses of ARC-520 administered 4-weekly (exact dosage not specified).", "study_duration": "Follow-up ranged from 28.9 to 30.4 months after the last dose.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:54.180168+00:00"}
{"study_id": 103206, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to assess the effectiveness and safety of Huazhi Rougan granule, which includes alanine aminotransferase (ALT) as a measured parameter, in treating non-alcoholic fatty liver compared to conventional therapy combined with silybin.", "results_summary": "The study found that Huazhi Rougan granule combined with conventional treatment significantly improved liver B-ultrasound results, reduced serological indexes (including ALT and AST), and increased high-density lipoprotein and total clinical effective rate. Adverse reactions were rare and mild.", "population_specificity": "Patients with non-alcoholic fatty liver (1,142 participants across 9 studies).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:58.621875+00:00"}
{"study_id": 103208, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of HDAC8 inhibitors, including an alanine hybrid compound, in breast cancer therapy.", "results_summary": "The study highlighted HDAC8 overexpression in breast cancer cells and suggested its oncogenic potential, with alanine hybrid compounds among the inhibitors showing therapeutic promise.", "population_specificity": "Breast cancer cells (in vitro studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:58.780466+00:00"}
{"study_id": 103205, "supplement_id": 863, "safety_score": "70", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the safety and pharmacokinetics of ModraDoc006/r (which includes alanine transferase as a biomarker) to establish the recommended phase 2 dose in patients with metastatic castration-resistant prostate cancer (mCRPC).", "results_summary": "The study reported dose-limiting toxicities, including grade 3 alanine transferase increase, diarrhea, and mucositis, but also observed promising clinical activity with PSA decreases >50% in 6/10 evaluable patients and two confirmed partial radiological responses. The recommended phase 2 dose was established at weekly ModraDoc006/r 30-20/200-100.", "population_specificity": "Patients with metastatic castration-resistant prostate cancer (mCRPC), either treatment-na\u00efve or following abiraterone or enzalutamide treatment.", "effective_dosage": "Various doses tested, including ModraDoc006 30-20/100-100, 30-20/200-200, 30-20/200-100, and 20-20/200-100, administered weekly.", "study_duration": "Not explicitly stated in the abstract.", "interactions": "Co-administered with ritonavir, a cytochrome P450 3A4 and P-glycoprotein inhibitor.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:59.946386+00:00"}
{"study_id": 103207, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, recommended phase II dose, and primary antitumor effects of GLS-010 (a PD-1 blocking monoclonal antibody) in patients with advanced, refractory lymphoma and solid tumors.", "results_summary": "GLS-010 demonstrated an acceptable safety profile with no dose-limiting toxicities observed in phase Ia. The dose of 240 mg Q2W was identified as the optimal recommended dose, showing favorable clinical response.", "population_specificity": "Patients with advanced, refractory lymphoma and solid tumors.", "effective_dosage": "1, 4, or 10 mg/kg Q2W; 240 mg Q3W or Q2W.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:00.139556+00:00"}
{"study_id": 103209, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the performance of hepatocellular carcinoma (HCC) prediction models in chronic hepatitis B (CHB) patients, including the role of baseline alanine aminotransferase in subgroup analyses.", "results_summary": "The study found that the REAL-B model exhibited the best discrimination and calibration for predicting HCC in CHB patients, with consistent results across subgroup analyses, including those based on baseline alanine aminotransferase levels.", "population_specificity": "Chronic hepatitis B (CHB) patients undergoing entecavir treatment (n=986 in the external validation cohort).", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 4.7 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:01.338610+00:00"}
{"study_id": 103213, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness and safety of laparoscopic versus open resection in treating hepatic hemangioma, including postoperative alanine aminotransferase (ALT) levels.", "results_summary": "The study found that laparoscopic surgery resulted in lower postoperative ALT and AST values compared to open surgery, indicating reduced liver stress. No significant differences were found in postoperative recurrence or other specific ALT-related outcomes.", "population_specificity": "Patients undergoing surgical treatment for hepatic hemangioma.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:01.642117+00:00"}
{"study_id": 103212, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study evaluated the immunologic impact of enzalutamide, including its effects on alanine aminotransferase (ALT) levels, but did not specifically assess Alanine as a supplement.", "results_summary": "The study noted grade 3 toxicity involving ALT elevation in two patients, but this was related to enzalutamide, not Alanine supplementation. No direct effects of Alanine were reported.", "population_specificity": "Patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) and normal testosterone levels.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:01.873660+00:00"}
{"study_id": 103211, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in improving liver injury and metabolic disorders in patients with metabolic associated fatty liver disease (MAFLD), including effects on alanine aminotransferase levels.", "results_summary": "The study found that GLP-1RAs significantly reduced alanine aminotransferase levels (WMD -10.73 U/L) and improved liver fat content, body weight, and waist circumference in MAFLD patients, with benefits outweighing adverse effects.", "population_specificity": "Patients with metabolic associated fatty liver disease (MAFLD), including those with type 2 diabetes mellitus (265 out of 396 patients).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:02.808695+00:00"}
{"study_id": 103214, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify factors detectable during the febrile phase of dengue that predict progression to severe disease, including biochemical markers like alanine aminotransferase (ALT).", "results_summary": "The study found that elevated alanine aminotransferase (ALT) concentrations during the febrile phase were associated with progression to severe dengue, with a standardized mean difference of 0.73 (95% CI 0.36 to 1.09).", "population_specificity": "Patients with dengue fever, including both adults and children.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:06.315640+00:00"}
{"study_id": 103215, "supplement_id": 863, "safety_score": "70", "efficacy_score": 78, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a higher dose of intravenous acetaminophen (15 mg/kg/dose every 6 hours) for treating patent ductus arteriosus (PDA) in preterm neonates.", "results_summary": "The study found that 78.2% of preterm neonates achieved successful PDA closure with the higher acetaminophen dose. Elevated alanine aminotransferase levels (indicating potential hepatotoxicity) occurred in 10 neonates, and 8 showed altered renal function tests (acute kidney injury).", "population_specificity": "Preterm neonates (\u226437 weeks gestational age) with hemodynamically significant PDA, including extreme, very, and late preterm subgroups.", "effective_dosage": "15 mg/kg/dose every 6 hours (intravenous).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:08.126473+00:00"}
{"study_id": 103218, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the role of HBV reactivation in allo-HSCT recipients and donors, including the significance of monitoring alanine transaminase (ALT) and HBV-DNA.", "results_summary": "The study highlights the importance of screening for HBV markers in allo-HSCT recipients and donors, recommending prophylactic antiviral therapy for HBsAg-positive recipients and regular ALT and HBV-DNA monitoring. Optimal antiviral therapy duration and monitoring intervals remain unresolved.", "population_specificity": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients and donors, particularly those with HBV infection or resolved HBV.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:10.722128+00:00"}
{"study_id": 103217, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and tolerability of direct-acting antiviral treatments (including effects on serum alanine transaminase levels) in patients with chronic hepatitis C, with or without cirrhosis.", "results_summary": "The study found that patients achieving sustained virologic response (SVR) showed a significant decrease in serum alanine transaminase (ALT) levels, indicating improved liver function. Higher initial ALT levels were associated with poorer SVR outcomes.", "population_specificity": "4,352 patients with chronic hepatitis C (with or without cirrhosis) from 36 institutions in Turkey.", "effective_dosage": "Not specified for alanine (study focused on antiviral regimens: ledipasvir/sofosbuvir\u00b1ribavirin or ombitasvir/paritaprevir/ritonavir\u00b1dasabuvir\u00b1ribavirin).", "study_duration": "12 or 24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:11.011550+00:00"}
{"study_id": 103216, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 6, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of durvalumab combined with either tremelimumab or danvatirsen in patients with relapsed/refractory DLBCL, not specifically focusing on Alanine.", "results_summary": "The study found that the combination therapy was generally well tolerated, with common adverse events including increased alanine aminotransferase/aspartate aminotransferase (grade 1-3). However, antitumor activity was limited, with an overall response rate of 6.3%.", "population_specificity": "Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who had received a median of 2 prior lines of systemic therapy.", "effective_dosage": "Durvalumab 20 mg/kg every 4 weeks plus either tremelimumab 1 mg/kg every 4 weeks or danvatirsen 2 or 3 mg/kg (administered on days 1, 3, 5, 8, 15, and 22, then every week).", "study_duration": "Treatment continued until disease progression.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:12.017370+00:00"}
{"study_id": 103219, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the noninferiority of a twice-daily versus a three-times-daily UFT/LV regimen for stage II/III colorectal cancer in an adjuvant setting.", "results_summary": "The twice-daily regimen showed noninferior 3-year disease-free survival rates compared to the three-times-daily regimen (81.4% vs. 79.4%), with no significant increase in adverse events. The most common adverse events were diarrhea, neutropenia, and liver enzyme increases, with similar rates between groups.", "population_specificity": "Patients with stage II/III colorectal cancer.", "effective_dosage": "Group A: 300 mg/m\u00b2 UFT three times daily; Group B: 300 mg/m\u00b2 UFT twice daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:12.163583+00:00"}
{"study_id": 103220, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "To examine the effect of therapeutic hypothermia on liver enzymes, including alanine aminotransferase (ALT), in patients with acute stroke.", "results_summary": "Therapeutic hypothermia was associated with a decrease in ALT values (from 27.50 to 26.50 IU/mL) without statistical significance. ALT values at admission correlated with the severity of the clinical picture (GCS) but not with NIHSS.", "population_specificity": "101 patients diagnosed with acute stroke (40 treated with hypothermia + conventional therapy, 61 with conventional therapy alone).", "effective_dosage": "Not specified (therapeutic hypothermia targeted 34\u00b0C to 35\u00b0C for up to 24 hours).", "study_duration": "Up to 24 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:12.672597+00:00"}
{"study_id": 103221, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers compared the effectiveness of tofogliflozin and pioglitazone in reducing hepatic steatosis (measured by MRI-PDFF) in NAFLD patients with type 2 diabetes mellitus.", "results_summary": "Both tofogliflozin and pioglitazone significantly reduced hepatic steatosis, with pioglitazone showing a greater reduction (-7.54% vs. -4.12%). Tofogliflozin also reduced body weight, while pioglitazone increased it. No life-threatening events or treatment-related deaths occurred.", "population_specificity": "NAFLD patients with type 2 diabetes mellitus and a hepatic fat fraction \u226510% (assessed by MRI-PDFF).", "effective_dosage": "20 mg tofogliflozin or 15-30 mg pioglitazone, orally, once daily.", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:14.096494+00:00"}
{"study_id": 103222, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify predictors of mortality in severe fever with thrombocytopenia syndrome (SFTS) cases, including the role of laboratory parameters like alanine transaminase.", "results_summary": "The study found that elevated alanine transaminase levels, among other markers, were significantly higher in fatal SFTS cases compared to nonfatal cases, suggesting its potential as a predictor of mortality.", "population_specificity": "208 SFTS-confirmed cases (189 survivors, 19 deaths) in three endemic cities, predominantly farmers (90.4%), median age 64 years.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:15.274986+00:00"}
{"study_id": 103223, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and efficacy of stent placement combined with intraluminal radiofrequency ablation and hepatic arterial infusion chemotherapy for advanced biliary tract cancers with biliary obstruction, not specifically studying alanine.", "results_summary": "The study found that alanine aminotransferase elevation was a common adverse event (37.5%) related to hepatic arterial infusion chemotherapy, but all adverse events were tolerable with no deaths reported.", "population_specificity": "Patients with advanced biliary tract cancers and biliary obstruction.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified for alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:16.086792+00:00"}
{"study_id": 103224, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether remote ischemic preconditioning (RIPC) could protect living liver donors and recipients by improving outcomes such as alanine transaminase levels and reducing complications.", "results_summary": "RIPC did not significantly improve alanine transaminase levels or reduce early allograft dysfunction, primary nonfunction, or postoperative complications in recipients. Limited protective effects were observed, such as lower creatinine levels in one group.", "population_specificity": "Living liver donors and pediatric liver transplant recipients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:18.260020+00:00"}
{"study_id": 103227, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of SGLT inhibitors on lipid metabolism and their efficacy in reducing weight, including the impact on alanine aminotransferase levels.", "results_summary": "SGLT inhibitors reduced alanine aminotransferase levels, indicating potential hepatoprotective effects, and improved lipid metabolism without significantly altering serum cholesterol levels.", "population_specificity": "Patients with type 2 diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:19.353785+00:00"}
{"study_id": 103225, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the performance of MET409, a structurally optimized FXR agonist, in patients with NASH, focusing on liver fat reduction and side effect profiles.", "results_summary": "MET409 significantly reduced liver fat content (55% at 80 mg, 38% at 50 mg) and achieved \u226530% ALT reduction in 50% (80 mg) and 31% (50 mg) of patients, though it increased LDL-C and caused mild-moderate pruritus in some cases.", "population_specificity": "Patients with non-alcoholic steatohepatitis (NASH).", "effective_dosage": "80 mg and 50 mg daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:19.928120+00:00"}
{"study_id": 103226, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the association of xanthine oxidoreductase (XOR) and its substrate with vascular complications in Japanese inpatients with type 2 diabetes, focusing on liver dysfunction and insulin resistance.", "results_summary": "Plasma XOR activity and xanthine levels correlated with metabolic markers (BMI, AST, ALT, \u03b3-GTP, insulin, HOMA-IR) and negatively with HDL cholesterol. XOR activity was also linked to diabetes duration, cardiovascular parameters, and was lower in patients with coronary artery disease.", "population_specificity": "94 Japanese inpatients with type 2 diabetes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:21.416963+00:00"}
{"study_id": 103229, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of probiotics or symbiotics, including changes in alanine levels, on body weight and serum metabolite profiles in women with obesity.", "results_summary": "The symbiotic group showed an increase in alanine levels, along with other metabolites, suggesting improved metabolic health. These changes were unique to the symbiotic intervention compared to probiotics or diet alone.", "population_specificity": "32 adult women with a BMI of 30-34.9 kg/m\u00b2", "effective_dosage": "Not specified", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:21.569458+00:00"}
{"study_id": 103228, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the incidence of HBV reactivation-related hepatitis in HBsAg-positive DLBCL patients receiving rituximab-containing chemotherapy and the effectiveness of different anti-HBV prophylactic therapies.", "results_summary": "The study found that HBsAg-positive patients had a higher 4-year cumulative incidence of HBV reactivation-related hepatitis compared to HBsAg-negative patients (8.0% vs 0.4%). Prophylactic use of entecavir (ETV) significantly reduced HBV reactivation-related hepatitis and mortality in HBsAg-positive patients.", "population_specificity": "HBsAg-positive and HBsAg-negative patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab-containing chemotherapy.", "effective_dosage": "Not specified", "study_duration": "Data collected between January 2004 and December 2014 (retrospective analysis)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:22.411296+00:00"}
{"study_id": 103230, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the incidence of hepatitis flare, HBV reactivation, and HBsAg seroclearance or seroreversion in patients with current or past HBV infection receiving immunotherapy.", "results_summary": "The study found that hepatitis flare occurred in 39.3% of HBsAg-positive and 30.4% of HBsAg-negative patients during immunotherapy, while HBV reactivation, HBsAg seroclearance, and seroreversion were rare (<1%). Current or past HBV infection did not impact the emergence of hepatic flare associated with immunotherapy.", "population_specificity": "Patients with current or past HBV infection who received immunotherapy in Hong Kong.", "effective_dosage": "Not specified", "study_duration": "Data collected from July 1, 2014, to December 31, 2019.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:24.175961+00:00"}
{"study_id": 103231, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the long-term safety and efficacy of REP 2139-Ca and pegIFN in achieving functional cure for HBV/HDV coinfection, including monitoring alanine aminotransferase (ALT) levels as a marker of liver health.", "results_summary": "The study found that HDV functional cure persisted in 7 of 11 participants, and HBV functional cure (with HBsAg seroconversion) persisted in 4 of 11 participants. Alanine aminotransferase (ALT) levels normalized in participants achieving functional cure, indicating improved liver health.", "population_specificity": "Participants with HBV/HDV coinfection who completed therapy in the REP 301 study.", "effective_dosage": "Not specified in the abstract.", "study_duration": "3.5 years of follow-up after therapy.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:25.093480+00:00"}
{"study_id": 103235, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the association between high BMI and disease severity in imported COVID-19 patients, including the role of biochemical indicators like alanine aminotransferase (ALT).", "results_summary": "Elevated ALT was identified as an independent risk factor associated with high BMI in COVID-19 patients, suggesting a potential link between liver injury and disease severity in this population.", "population_specificity": "Imported COVID-19 patients in Zhejiang province, China, with BMI \u2265 24 compared to those with BMI < 24.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:28.860563+00:00"}
{"study_id": 103233, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize the characteristics of COVID-19 patients and explore risk factors of disease progression, including the role of laboratory indicators like alanine aminotransferase (ALT).", "results_summary": "The study found that elevated ALT levels were associated with disease severity in COVID-19 patients, suggesting liver involvement. However, the abstract does not focus on alanine supplementation or its direct effects.", "population_specificity": "COVID-19 patients (16,526 individuals across 90 studies).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:29.811591+00:00"}
{"study_id": 103232, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the non-inferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis, not Alanine.", "results_summary": "The study found posaconazole was non-inferior to voriconazole in all-cause mortality up to day 42, with fewer treatment-related adverse events. Alanine was not the focus of the study.", "population_specificity": "Participants aged 13+ with invasive aspergillosis, weighing \u226540 kg, from 91 sites in 26 countries.", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Up to 12 weeks (Alanine not studied).", "interactions": "None mentioned (Alanine not studied).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:30.854294+00:00"}
{"study_id": 103237, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of combination therapy (entecavir or tenofovir with Peg-IFN\u03b1) on long-term reduction in HBsAg levels in chronic HBV infection.", "results_summary": "Some studies showed promising results for combination therapy, but there is no robust evidence that it is superior to monotherapy. Large studies are needed to assess long-term safety and efficacy for increasing HBsAg seroclearance rates.", "population_specificity": "Patients with chronic hepatitis B virus (HBV) infection.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:31.501703+00:00"}
{"study_id": 103236, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to analyze clinical and biological characteristics, including alanine aminotransferase (ALAT) levels, in COVID-19 patients to identify factors predictive of disease severity.", "results_summary": "Elevated ALAT levels during admission and hospitalization were strongly associated with progression to severe COVID-19, suggesting its potential as a biomarker for disease severity. The study did not evaluate ALAT as a therapeutic intervention.", "population_specificity": "134 hospitalized COVID-19 patients (median age 53 years, 54.5% male) from the North African Mediterranean region.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:32.002624+00:00"}
{"study_id": 103238, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not evaluate Alanine; it focuses on comparing the efficacy and safety of sitafloxacin versus moxifloxacin for treating community-acquired pneumonia in Chinese adults.", "results_summary": "The study found that sitafloxacin (100 mg qd or bid) was non-inferior to moxifloxacin (400 mg qd) in clinical efficacy for treating CAP, with comparable safety profiles.", "population_specificity": "Chinese adults with community-acquired pneumonia (CAP)", "effective_dosage": "Sitafloxacin 100 mg once daily (qd) or 100 mg twice daily (bid); moxifloxacin 400 mg qd", "study_duration": "7-10 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:32.184181+00:00"}
{"study_id": 103239, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the diagnostic significance of carbohydrate-deficient transferrin (CDT) in chronic alcoholism, comparing it with other biochemical markers including alanine aminotransferase (ALT).", "results_summary": "The study found that CDT was a better indicator of alcoholism compared to ALT and other markers, with high sensitivity (85.5%) and specificity (89.6%) at a cutoff of 1.25%. However, the correlation between CDT and daily alcohol consumption was weak.", "population_specificity": "Chinese population, including healthy subjects, nonalcoholic liver disease patients, and alcoholics.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:32.967308+00:00"}
{"study_id": 103234, "supplement_id": 863, "safety_score": "40", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of ribociclib and everolimus in pediatric patients, including assessing ribociclib concentrations in plasma and tumor tissue.", "results_summary": "The study found that ribociclib and everolimus were generally well-tolerated, but grade 4 alanine aminotransferase elevation was observed in one patient at dose level 2. Potential therapeutic ribociclib concentrations were achieved in CSF and tumor tissue, though with interpatient variability.", "population_specificity": "Pediatric patients (median age 10.3 years, range 3.9-20.4) with brain tumors.", "effective_dosage": "Ribociclib at 350 mg/m\u00b2 (surgical cohort) and RP2D of ribociclib 120 mg/m\u00b2 with everolimus 1.2 mg/m\u00b2.", "study_duration": "Ribociclib administered daily for 21 days and everolimus for 28 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:33.323819+00:00"}
{"study_id": 103244, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were attempting to determine the role of cation-chloride cotransporters (CCCs) in stroke and their potential as pharmacological targets.", "results_summary": "The abstract does not provide specific findings regarding Alanine's effects.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:38.494801+00:00"}
{"study_id": 103242, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to determine the incidence of liver injury in transgender individuals using gender-affirming hormone therapy, focusing on liver enzyme levels, including alanine aminotransferase (ALT).", "results_summary": "The study found a very low incidence of liver injury (0.1-0.6%) in transgender individuals after 12 months of hormone therapy, with no significant safety concerns related to ALT elevation. Liver enzyme monitoring was deemed unnecessary for this population.", "population_specificity": "1933 transgender individuals (889 transgender women and 1044 transgender men).", "effective_dosage": "Not specified.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:38.554155+00:00"}
{"study_id": 103240, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of BAT8001, an antibody-drug conjugate, in HER2-positive breast cancer patients, not specifically Alanine.", "results_summary": "The study reported dose-limiting toxicities and adverse events related to BAT8001, including elevated alanine aminotransferase in 6.9% of patients, but did not focus on Alanine's effects.", "population_specificity": "HER2-positive locally advanced or metastatic breast cancer patients with evaluable lesions and ECOG performance status of 0 or 1.", "effective_dosage": "Not applicable (study focused on BAT8001 doses: 1.2, 2.4, 3.6, 4.8, and 6.0 mg/kg).", "study_duration": "Administered in 21-day cycles (enrollment from March 2017 to May 2018).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:39.064474+00:00"}
{"study_id": 103241, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to investigate the efficacy and safety of tenofovir disoproxil fumarate in reducing disease progression in patients with chronic hepatitis B and minimally raised alanine aminotransferase (ALT).", "results_summary": "Tenofovir disoproxil fumarate significantly reduced liver fibrosis progression (26% vs. 47% in placebo) and acute hepatitis flare (3% vs. 16% in placebo), but its effect on necroinflammation was non-significant. Adverse events were similar between groups, with no deaths reported.", "population_specificity": "Patients aged 25-70 with chronic hepatitis B, substantial viraemia, and minimally raised ALT (1-2x ULN), excluding those with liver cirrhosis or prior antiviral treatment.", "effective_dosage": "300 mg oral tenofovir disoproxil fumarate once daily.", "study_duration": "3 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:40.214786+00:00"}
{"study_id": 103243, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effect of dietary interventions with different macronutrient compositions on hepatic steatosis attenuation and serum levels of alanine aminotransferase in adults and elderly with NAFLD.", "results_summary": "The study found that hypocaloric diets had effects on hepatic steatosis and serum alanine aminotransferase levels, while reduced macronutrient interventions showed no efficacy. Most results were related to caloric restriction rather than specific macronutrient modifications.", "population_specificity": "Adults and elderly (age \u2265 60 years) with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:40.299609+00:00"}
{"study_id": 103245, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to identify predictors of biochemical and histological remission in patients with autoimmune hepatitis (AIH), focusing on factors like serum IgG levels and liver fibrosis.", "results_summary": "Lower serum IgG levels, less liver fibrosis at diagnosis, and rapid response to immunosuppressive therapy were reliable predictors of remission. Patients achieving remission had significantly lower IgG levels and faster biochemical response times.", "population_specificity": "705 patients with autoimmune hepatitis (AIH) and complete follow-up data.", "effective_dosage": "Not specified", "study_duration": "3 years (for histological remission assessment)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:40.936983+00:00"}
{"study_id": 103246, "supplement_id": 863, "safety_score": "85", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether a standardized extract of Nasturtium officinale (SENO) could improve or maintain serum lipid and oxidative stress markers in overweight individuals.", "results_summary": "SENO significantly improved low-density lipoprotein cholesterol, creatinine, and lipid peroxidation levels but did not significantly affect total serum cholesterol, triacylglycerol, high-density lipoprotein, or other oxidative stress and liver enzyme markers.", "population_specificity": "Overweight individuals with physical disabilities.", "effective_dosage": "750 mg/kg/d of SENO.", "study_duration": "5 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:41.390438+00:00"}
{"study_id": 103247, "supplement_id": 863, "safety_score": "40", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety and antitumor activity of mavorixafor (a CXCR4 inhibitor) in combination with nivolumab for metastatic clear cell renal cell carcinoma (ccRCC) patients unresponsive to nivolumab monotherapy.", "results_summary": "The combination therapy showed potential antitumor activity, with one partial response and stable disease in all patients who had progressive disease at baseline. However, four patients discontinued due to treatment-related adverse events, including elevated alanine aminotransferase in two patients.", "population_specificity": "Patients with metastatic clear cell renal cell carcinoma (ccRCC) unresponsive to nivolumab monotherapy (median age 65 years).", "effective_dosage": "Mavorixafor 400 mg daily plus nivolumab 240 mg intravenously every 2 weeks.", "study_duration": "Median duration of stable disease was 6.7 months (range: 3.7-14.7).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:43.750591+00:00"}
{"study_id": 103248, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers sought to examine the potential role of liver fibrosis scores (LFSs), including those involving alanine aminotransferase (ALT), in predicting long-term cardiovascular outcomes in patients with stable coronary artery disease after elective PCI.", "results_summary": "Higher LFSs, including those involving ALT ratios, were associated with significantly increased risk of cardiovascular events, and adding these scores to established risk models improved predictive ability.", "population_specificity": "4003 patients with stable coronary artery disease undergoing elective PCI.", "effective_dosage": "Not specified", "study_duration": "Average follow-up of 5.0\u00b11.6 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:48.756732+00:00"}
{"study_id": 103250, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify metabolic pathways, including alanine metabolism, that are altered in Alzheimer's disease to uncover potential therapeutic targets.", "results_summary": "The study found altered expression of alanine and related metabolites in Alzheimer's disease, suggesting disrupted metabolic pathways that could contribute to disease mechanisms. These findings highlight potential biochemical targets for therapeutic intervention.", "population_specificity": "AD subjects and animal models of Alzheimer's disease.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:50.160017+00:00"}
{"study_id": 103251, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and recommended dosage of olaratumab in combination with chemotherapy regimens in children with relapsed/refractory solid or central nervous system tumors, not specifically studying alanine.", "results_summary": "The study reported dose-limiting toxicities related to alanine aminotransferase (ALT) elevations during olaratumab monotherapy and combination therapy, but the focus was on olaratumab's safety and pharmacokinetics, not alanine's effects.", "population_specificity": "Children and adolescents (<18 years) with relapsed/refractory solid or central nervous system tumors.", "effective_dosage": "Not applicable (study focused on olaratumab, not alanine).", "study_duration": "21-day cycles for multiple cycles (exact duration not specified).", "interactions": "None mentioned (study focused on olaratumab-chemotherapy interactions).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:53.936949+00:00"}
{"study_id": 103253, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate risk factors for ARDS in patients with severe acute pancreatitis (SAP), not specifically focusing on Alanine.", "results_summary": "The study found no significant differences in alanine aminotransferase levels between SAP patients with and without ARDS, indicating Alanine was not a significant factor in ARDS development.", "population_specificity": "281 SAP patients treated in a hospital from June 2018 to May 2020.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:54.229788+00:00"}
{"study_id": 103252, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of crizotinib monotherapy in patients with alectinib-refractory, EML4-ALK-positive NSCLC, focusing on the role of MET pathway activation in resistance.", "results_summary": "The study found a 33.3% overall response rate to crizotinib, with common adverse events including increased AST/ALT ratio (44%) and appetite loss (33%). Progression-free survival was short (median 2.2 months), but median survival time was 24.1 months.", "population_specificity": "Patients with ALK-rearranged, alectinib-refractory, EML4-ALK-positive NSCLC.", "effective_dosage": "Not specified", "study_duration": "Median treatment interval of 50 days (range 20-433 days)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:54.285356+00:00"}
{"study_id": 103254, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were examining the role of glutamine metabolism in cancer cells, particularly focusing on the transporter ASCT2, which mediates the uptake of alanine, serine, and cysteine.", "results_summary": "The abstract highlights that increased glutaminolysis in cancer cells is linked to higher expression of ASCT2, suggesting a potential metabolic dependency on glutamine and related amino acids like alanine for cancer progression.", "population_specificity": "Cancer cells (in vitro or preclinical context, not specified).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:55.293561+00:00"}
{"study_id": 103255, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review novel PEG-mimetic peptides, including proline/alanine/serine repeat sequences, for enhancing the pharmacokinetic profile of therapeutic proteins.", "results_summary": "The study highlights that PEG-mimetic peptides, such as proline/alanine/serine sequences, offer advantages like biodegradability, low immunogenicity, and product homogeneity, making them a preferred technology for extending the plasma half-life of therapeutic proteins.", "population_specificity": "Not specified (review article)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:56.752579+00:00"}
{"study_id": 103256, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore the impact of BMI on the efficacy and safety of tofacitinib in patients with active psoriatic arthritis (PsA).", "results_summary": "Tofacitinib showed greater efficacy than placebo in PsA patients, regardless of baseline BMI, though reduced efficacy was observed in patients with BMI \u226535 kg/m\u00b2.", "population_specificity": "Patients with active psoriatic arthritis (PsA).", "effective_dosage": "Tofacitinib 5 mg or 10 mg twice daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:59.213839+00:00"}
{"study_id": 103249, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the prolonged efficacy and safety of besifovir dipivoxil maleate (BSV) in treatment-naive chronic hepatitis B patients, comparing it to tenofovir disoproxil fumarate (TDF).", "results_summary": "BSV maintained potent antiviral efficacy over 192 weeks with no drug-resistant mutations and preserved bone mineral density and renal function, while TDF-BSV patients showed initial worsening followed by recovery after switching to BSV.", "population_specificity": "Treatment-naive chronic hepatitis B patients.", "effective_dosage": "Not specified in the abstract.", "study_duration": "192 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:00.663702+00:00"}
{"study_id": 103259, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of silymarin in reducing transaminase levels (including alanine aminotransferase) and improving liver histology in individuals with NAFLD.", "results_summary": "Silymarin treatment significantly reduced transaminase levels compared to placebo, irrespective of weight loss, though the study noted potential flaws in the quality of included studies.", "population_specificity": "Individuals with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:01.676969+00:00"}
{"study_id": 103258, "supplement_id": 863, "safety_score": "65", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine the maximum tolerated dose, preliminary efficacy, and pharmacokinetics of intravenous lipid emulsion fenretinide in patients with advanced solid tumors.", "results_summary": "The study found that fenretinide emulsion had a manageable safety profile with common adverse events including anemia, hypertriglyceridemia, and elevated liver enzymes. Five patients had stable disease, but no objective responses were observed, indicating minimal single-agent activity.", "population_specificity": "Patients with advanced solid tumors refractory to standard treatments.", "effective_dosage": "Five different dose cohorts evaluated between 905 mg/m\u00b2 (specific frequency not detailed).", "study_duration": "Continuous infusion for five consecutive days in 21-day cycles.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:01.809933+00:00"}
{"study_id": 103262, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate clinical characteristics and risk factors for severe COVID-19 cases, including abnormal laboratory findings such as alanine aminotransferase levels.", "results_summary": "The study found that 28% of severe COVID-19 cases had increased alanine aminotransferase levels, indicating potential liver dysfunction, but did not assess alanine's direct effects or efficacy.", "population_specificity": "Severe COVID-19 patients.", "effective_dosage": "Not available.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:02.174548+00:00"}
{"study_id": 103260, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of intracoronary autologous bone marrow mesenchymal stem cell (BM-MSC) transplantation in patients with ST-segment elevation myocardial infarction (STEMI), including monitoring alanine transaminase (ALT) levels.", "results_summary": "The study found no significant improvement in myocardial activity or LV function with BM-MSC transplantation. ALT levels in the BM-MSC group were significantly lower than in the control group, but no direct efficacy of alanine was demonstrated.", "population_specificity": "Patients aged 39-76 years with STEMI from six hospitals in Beijing.", "effective_dosage": "Not specified for alanine.", "study_duration": "12 months of follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:02.688337+00:00"}
{"study_id": 103261, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in HCV-infected patients with severe renal impairment.", "results_summary": "The study found that SOF/VEL with or without low-dose RBV was effective, achieving high sustained virological response rates, and was well-tolerated in patients with severe renal impairment.", "population_specificity": "HCV-infected patients with chronic kidney disease stage 4 or 5, including those with compensated and decompensated liver disease.", "effective_dosage": "SOF/VEL (400/100 mg/day) alone or with low-dose RBV (200 mg/day).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:03.329684+00:00"}
{"study_id": 103263, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify parameters influencing micafungin pharmacokinetics in Chinese sepsis patients and optimize dosage for pharmacodynamic targets.", "results_summary": "Alanine aminotransferase significantly influenced micafungin clearance. Higher micafungin doses (200-300 mg daily) were needed to achieve effective plasma levels against certain Candida species.", "population_specificity": "32 Chinese patients with sepsis in the intensive care unit.", "effective_dosage": "200-300 mg micafungin daily.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:07.639892+00:00"}
{"study_id": 103264, "supplement_id": 863, "safety_score": "85", "efficacy_score": 95, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and effectiveness of tenofovir alafenamide fumarate (TAF) during pregnancy for preventing mother-to-child transmission of hepatitis B virus (HBV).", "results_summary": "TAF was well tolerated with minimal adverse effects (primarily nausea) and no birth defects in infants. The HBsAg-positive rate in infants was 0% at 7 months, demonstrating high efficacy in preventing HBV transmission.", "population_specificity": "Pregnant women with HBV DNA levels >200,000 IU/mL and their infants.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Mean treatment duration of 11.0 weeks (from gestational weeks 24-35 to delivery).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:08.195647+00:00"}
{"study_id": 103265, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the efficacy and safety of Tripterygium wilfordii Hook F. (TwHF) in treating osteoarticular lesions in SAPHO syndrome, with a focus on Alanine aminotransferase elevation as an adverse event.", "results_summary": "The study found significant efficacy in disease remission with TwHF, but one patient developed severe Alanine aminotransferase elevation, leading to discontinuation of treatment. No other severe adverse events were reported.", "population_specificity": "Patients with SAPHO syndrome.", "effective_dosage": "1.0-mg/kg/day and 1.5-mg/kg/day.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:08.828371+00:00"}
{"study_id": 103269, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of anticoagulants, including their impact on alanine aminotransferase (ALT) levels, in animal models of chronic liver diseases.", "results_summary": "The study found that anticoagulants reduced ALT levels (mean difference = -82.7) and other markers of hepatic injury, suggesting a potential antifibrotic effect, but had no impact on animal survival.", "population_specificity": "Animal models of chronic liver diseases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:10.075827+00:00"}
{"study_id": 103268, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety profile of EGFR-TKIs, including adverse events such as increased alanine aminotransferase (ALT), in cancer patients.", "results_summary": "The study found that increased ALT (38.9%) was among the most frequently observed all-grade adverse events in patients treated with EGFR-TKIs, but it did not specifically assess the safety or efficacy of alanine as a supplement.", "population_specificity": "Patients with various cancers enrolled in randomized controlled trials (RCTs).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:10.140055+00:00"}
{"study_id": 103266, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study investigated the effect of adding everolimus to letrozole in ovarian-suppressed premenopausal women with HR+, HER2- recurrent/metastatic breast cancer, not specifically focused on Alanine.", "results_summary": "The abstract mentions alanine aminotransferase elevation as a common grade 3/4 adverse event in the EVE arm, but no specific results about Alanine's effects are provided.", "population_specificity": "Premenopausal women with HR+, HER2- recurrent/metastatic breast cancer.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Until disease progression or unacceptable toxicity (median follow-up 32.4 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:10.421172+00:00"}
{"study_id": 103267, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to estimate the effect of isoniazid preventive therapy with antiretroviral therapy (ART) on tuberculosis prevention and mortality among people with HIV, not specifically focused on Alanine.", "results_summary": "The study found that isoniazid preventive therapy with ART reduced tuberculosis risk (HR 0\u00b768) but did not significantly reduce mortality (HR 0\u00b769). Alanine aminotransferase elevation was noted in 2.5% of participants, but no detailed analysis was provided.", "population_specificity": "HIV-positive adults (age \u226515 years) on ART.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Follow-up duration varied, with up to 8584\u00b78 person-years for tuberculosis outcomes.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:10.686335+00:00"}
{"study_id": 103270, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of ursodeoxycholic acid (UDCA) in lowering alanine aminotransferase (ALT) levels in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The meta-analysis found that UDCA treatment significantly reduced ALT levels (p=0.007), with notable effects in European populations, individuals over 50, and longer-duration studies. However, further validation is needed to confirm UDCA's efficacy in NAFLD.", "population_specificity": "Patients with NAFLD, specifically subgroups from Europe, individuals older than 50, and those in longer-duration studies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:11.890821+00:00"}
{"study_id": 103273, "supplement_id": 863, "safety_score": "75", "efficacy_score": null, "quality_score": 80, "study_goal": "The researchers aimed to examine real-world safety data, including laboratory test abnormalities and adverse health conditions, in new users of oral multiple sclerosis disease-modifying therapies (DMTs), with a focus on elevated alanine aminotransferase (ALT) levels.", "results_summary": "The study found that short-term incidences of abnormal laboratory results, such as elevated ALT, were consistent with pivotal clinical trial findings, but longer-term safety data are still needed.", "population_specificity": "Persons with multiple sclerosis (PwMS) in two Canadian provinces.", "effective_dosage": "Not specified", "study_duration": "Up to 2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:17.556100+00:00"}
{"study_id": 103272, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the maximum tolerated dose, pharmacokinetics, and safety profile of rucaparib when combined with bevacizumab in patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.", "results_summary": "The study found that rucaparib at 600 mg twice daily caused dose-limiting toxicities, including increased alanine aminotransferase levels, leading to a maximum tolerated dose of 500 mg twice daily. No pharmacokinetic interactions were observed between rucaparib and bevacizumab.", "population_specificity": "Patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.", "effective_dosage": "Rucaparib doses of 400 mg, 500 mg, or 600 mg twice daily; bevacizumab 15 mg/kg every 21 days.", "study_duration": "28 days for rucaparib; bevacizumab administered at day 1 every 21 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:17.921083+00:00"}
{"study_id": 103271, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the long-term safety of tolvaptan, particularly focusing on liver enzyme elevations (including alanine aminotransferase) in patients with autosomal dominant polycystic kidney disease (ADPKD).", "results_summary": "The study found that while liver enzyme elevations (ALT/AST) were common, increased monitoring frequency (monthly for the first 18 months) helped detect and manage these elevations effectively. No new safety signals emerged during the long-term extension.", "population_specificity": "Patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Median exposure during the extension was 651 days (interquartile range, 538-924), with cumulative exposure up to 11 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:18.490988+00:00"}
{"study_id": 103279, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a formulated food containing prebiotics and dietary fiber could improve NAFLD by altering intestinal microbiota and its metabolites, including potential effects on alanine aminotransferase levels.", "results_summary": "The study planned to assess the efficacy of formulated food in reducing hepatic steatosis (measured by MRS-PDFF) and improving liver function, glycolipid metabolism, and systemic inflammation over 24 weeks, with follow-up until week 36. Changes in intestinal microbiota abundance and diversity were also explored.", "population_specificity": "Adult patients (18-75 years) with NAFLD and elevated alanine aminotransferase (1.5-5 times ULN) or biopsy-confirmed NASH (n=120).", "effective_dosage": "Not specified", "study_duration": "24 weeks (with follow-up until week 36)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:19.747153+00:00"}
{"study_id": 103276, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the overall survival benefits of dacomitinib versus gefitinib in patients with advanced NSCLC and EGFR-activating mutations, not specifically to evaluate alanine.", "results_summary": "The study found that dacomitinib improved overall survival compared to gefitinib, with a hazard ratio of 0.748. Increased alanine aminotransferase was noted as a common adverse event in the gefitinib arm (40.2%).", "population_specificity": "Adults with newly diagnosed advanced NSCLC and EGFR-activating mutations (exon 19 deletion or exon 21 L858R substitution), excluding those with CNS metastases.", "effective_dosage": "Not applicable (study did not focus on alanine supplementation).", "study_duration": "Median follow-up of 47.9 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:19.900593+00:00"}
{"study_id": 103278, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of statins and fibrates on various laboratory parameters, including alanine aminotransferase (ALT), in Japanese patients with dyslipidemia.", "results_summary": "The study found that fibrates had a greater effect on reducing ALT levels compared to statins, with a statistically significant difference (P=0.003). The changes in ALT levels were part of broader differences in laboratory parameters between the two drug classes.", "population_specificity": "Japanese patients with dyslipidemia newly treated with statin or fibrate monotherapy.", "effective_dosage": "Not specified", "study_duration": "Up to 12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:20.068416+00:00"}
{"study_id": 103275, "supplement_id": 863, "safety_score": "60", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and antitumor activity of ASP3026, a second-generation ALK inhibitor, in Japanese patients with solid tumors.", "results_summary": "The study found that ASP3026 had a tolerable safety profile at a 200-mg dose, with common adverse events including nausea, decreased appetite, and fatigue. Partial responses were observed in two patients, one with Ewing sarcoma and another with an ALKr-positive inflammatory myofibroblastic tumor.", "population_specificity": "Japanese patients with solid tumors.", "effective_dosage": "Daily doses of 25 mg, 50 mg, 75 mg, 125 mg, 200 mg, or 325 mg.", "study_duration": "From 1 June 2011 to 20 January 2014 (exact duration per patient not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:20.123594+00:00"}
{"study_id": 103280, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare clinical manifestations and laboratory findings, including alanine transaminase levels, in COVID-19 patients from Eastern and Western regions.", "results_summary": "The study found that COVID-19 patients from the West had significantly higher levels of alanine transaminase compared to those from the East, indicating more severe liver damage in Western patients. No direct assessment of alanine's therapeutic or supplemental effects was conducted.", "population_specificity": "COVID-19 patients from East and South-East Asia (China, South Korea, Thailand) and the West (United States, Italy, France, Iran).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:20.939642+00:00"}
{"study_id": 103283, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to analyze laboratory values, including alanine aminotransferase (ALT), in transgender patients undergoing hormone therapy (HT) to determine when values stabilize and their long-term impacts.", "results_summary": "The study found that alanine aminotransferase (ALT) increased beyond 1 year in transgender men (TM) (P < 0.001), indicating a long-term change in this analyte during HT.", "population_specificity": "Transgender women (TW) and transgender men (TM) undergoing hormone therapy.", "effective_dosage": "Not specified", "study_duration": "5 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:25.780370+00:00"}
{"study_id": 103282, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether increased IL-18 levels are associated with NAFLD and liver injury in people with HIV (PWH), with alanine aminotransferase (ALT) as one of the measured markers.", "results_summary": "The study found that ALT levels were higher in PWH compared to controls, suggesting potential liver injury, but the abstract does not directly link these findings to alanine supplementation or its effects.", "population_specificity": "People with HIV (PWH) and individuals without HIV in the Boston area, excluding those with hepatitis B, hepatitis C, or excessive alcohol use.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:26.031874+00:00"}
{"study_id": 103281, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer, not specifically Alanine.", "results_summary": "The study found that abiraterone acetate plus prednisolone demonstrated a 55.1% prostate-specific antigen response rate, but Alanine aminotransferase increase was a common adverse event (12.0% \u2265grade 3).", "population_specificity": "Patients with chemotherapy-na\u00efve early metastatic castration-resistant prostate cancer who failed first-line androgen deprivation therapy.", "effective_dosage": "Not applicable (study focused on abiraterone acetate and prednisolone, not Alanine).", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:26.152999+00:00"}
{"study_id": 103288, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers compared the epidemiological and clinical characteristics of SARS-CoV-2 infection between adults and children, not specifically studying Alanine.", "results_summary": "The study found no significant differences in clinical characteristics between children and adults with COVID-19, except for higher neutrophil percentages in adults. Alanine was not discussed in the abstract.", "population_specificity": "52 patients with COVID-19 (38 adults and 14 children).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:28.204204+00:00"}
{"study_id": 103285, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety and efficacy of liraglutide in patients with non-alcoholic fatty liver disease (NAFLD), focusing on changes in hepatic fat content and alanine aminotransferase (ALT) levels.", "results_summary": "Liraglutide produced a non-significant decrease in hepatic fat content and ALT levels but significantly reduced body mass index and serum triglyceride levels, primarily in patients with type 2 diabetes. It was associated with increased gastrointestinal adverse events but no other safety issues.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD), including those with type 2 diabetes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:28.640870+00:00"}
{"study_id": 103287, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the durability of HBV suppression in HIV-HBV co-infected patients treated with lamivudine alone or lamivudine-tenofovir, focusing on baseline HBV DNA levels.", "results_summary": "Lamivudine alone showed highly durable HBV suppression (up to 5 years) in patients with baseline HBV DNA <6 log10 IU/mL, while lamivudine-tenofovir was more effective for higher baseline HBV DNA levels. Viral rebound was rare (8%) in suppressed patients, and no alanine transaminase flares were observed.", "population_specificity": "HIV-HBV co-infected adults in Uganda and Zimbabwe.", "effective_dosage": "Not specified", "study_duration": "Up to 4.8 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:29.157077+00:00"}
{"study_id": 103286, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the frequency of hepatotoxicity based on liver chemistry in children with juvenile idiopathic arthritis (JIA) receiving methotrexate (MTX).", "results_summary": "The study found that 28% of children receiving MTX developed hepatotoxicity, with higher ALT and AST levels and lower ALP levels compared to controls. No significant differences were observed in age, sex, weight, type of JIA, or duration of MTX treatment.", "population_specificity": "Children with juvenile idiopathic arthritis (JIA) attending the Pediatric Rheumatology Unit, Cairo University Pediatric Hospital, Egypt.", "effective_dosage": "Not specified", "study_duration": "Data were collected from January 2018 to December 2018 (exact duration of MTX therapy not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:30.362568+00:00"}
{"study_id": 103289, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the role of alanine aminotransferase (ALT) as a biomarker for treatment response and remission in autoimmune hepatitis (AIH).", "results_summary": "The study found that prolonged and stringent biochemical remission, indicated by lower ALT levels and normal IgG, may allow some AIH patients to discontinue medications. However, most patients require lifelong maintenance treatment.", "population_specificity": "Patients with autoimmune hepatitis (AIH), including subtypes with chronic insidious onset and acute-onset AIH.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:33.750846+00:00"}
{"study_id": 103291, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma, not specifically Alanine.", "results_summary": "The study found superior clinical outcomes with pembrolizumab plus axitinib over sunitinib in terms of overall survival and progression-free survival, but did not specifically evaluate Alanine.", "population_specificity": "Adults (\u226518 years old) with treatment-naive, advanced renal cell carcinoma with clear cell histology.", "effective_dosage": "Not applicable (study did not focus on Alanine).", "study_duration": "Median follow-up of 30.6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:34.434470+00:00"}
{"study_id": 103290, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the safety and dosing of niraparib (NIR) in combination with temozolomide (TMZ) or irinotecan (IRN) in patients with pretreated Ewing sarcoma (ES), not specifically Alanine.", "results_summary": "The study found that the combination of NIR with TMZ or IRN was tolerable but required lower doses compared to conventional cytotoxic combinations. Adverse events included grade 3 alanine aminotransferase elevation in one patient in arm 2.", "population_specificity": "Patients with pretreated Ewing sarcoma (23 males and 6 females).", "effective_dosage": "NIR at 200 mg every day on days 1-7 plus TMZ at 30 mg/m\u00b2 (specific dosage for Alanine not provided).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned for Alanine specifically.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:35.824753+00:00"}
{"study_id": 103292, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the efficacy of bicyclol, a hepatoprotectant, in improving blood biomarkers (including alanine transaminase, ALT) in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Bicyclol significantly improved liver function and blood lipid biomarkers, including ALT and AST, in NAFLD patients, with no serious adverse events reported. The total effective rate was higher in the bicyclol group compared to controls.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:37.544510+00:00"}
{"study_id": 103293, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the efficacy and safety of Saroglitazar in patients with non-alcoholic fatty liver disease (NAFLD) and diabetic dyslipidemia (DD), focusing on its impact on liver enzymes like alanine transaminase (ALT).", "results_summary": "The study found significant reductions in ALT, AST, liver stiffness measurement (LSM), and controlled attenuation parameter (CAP), along with improvements in glycated hemoglobin and lipid parameters after 24 weeks of Saroglitazar treatment.", "population_specificity": "Patients with diabetic dyslipidemia and NAFLD (mean age 50.4 \u00b1 12.3 years, 78.5% males, mean BMI 28.8 \u00b1 4.2).", "effective_dosage": "4 mg once daily", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:38.025837+00:00"}
{"study_id": 103294, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of vitamin E in treating paediatric non-alcoholic fatty liver disease (NAFLD), including its impact on alanine transaminase (ALT) levels.", "results_summary": "The study found no significant changes in ALT levels or other liver function indicators, though vitamin E improved blood lipids (LDL and total cholesterol). Fasting glucose levels increased with treatment durations \u226412 months.", "population_specificity": "Children with non-alcoholic fatty liver disease (NAFLD)", "effective_dosage": "Not specified", "study_duration": "Varied, with some interventions lasting \u226412 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:38.067897+00:00"}
{"study_id": 103295, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether resveratrol supplementation affects alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The meta-analysis found no significant overall effect of resveratrol supplementation on ALT or AST levels in NAFLD patients, though subgroup analyses showed reductions in younger participants, lower dosages, longer durations, and those with BMI <30 kg/m\u00b2.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "<1000 mg/day (subgroup analysis).", "study_duration": ">12 weeks (subgroup analysis).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:38.804303+00:00"}
{"study_id": 103297, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to consolidate evidence on the association between SGLT2 inhibitors and beneficial hepatic outcomes, including effects on liver enzymes like alanine aminotransferase, in patients with type 2 diabetes and NAFLD.", "results_summary": "Five systematic reviews indicated that SGLT2 inhibitors could effectively decrease liver fat and liver parameters such as alanine aminotransferase and gamma-glutamyl transferase in NAFLD patients. However, no evidence of liver fibrosis improvement was found, and the methodological quality of the reviews was relatively low.", "population_specificity": "Patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:42.751796+00:00"}
{"study_id": 103296, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the antitumour activity of GX-188E therapeutic DNA vaccine plus pembrolizumab in patients with recurrent or advanced cervical cancer, not specifically Alanine.", "results_summary": "The study found that the combination therapy showed preliminary antitumour activity, with 42% of evaluable patients achieving an overall response. Treatment-related adverse events were manageable, with no treatment-related deaths reported.", "population_specificity": "Patients with recurrent or advanced, inoperable HPV-positive (HPV-16 or HPV-18) cervical cancer who had progressed after standard therapy.", "effective_dosage": "2 mg GX-188E intramuscularly at weeks 1, 2, 4, 7, 13, and 19, with optional dose at week 46; 200 mg pembrolizumab intravenously every 3 weeks.", "study_duration": "Up to 2 years or until disease progression.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:43.798737+00:00"}
{"study_id": 103299, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the effects of convalescent plasma therapy in patients with severe COVID-19 pneumonia, not Alanine.", "results_summary": "The study found no direct results regarding Alanine's effects, as it focused on convalescent plasma therapy.", "population_specificity": "Patients with severe COVID-19 pneumonia in Wuhan, China.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:45.619529+00:00"}
{"study_id": 103298, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the impact of baseline liver function, including alanine aminotransferase (ALT) levels, on COVID-19-related outcomes such as mortality, ICU admissions, and severe complications.", "results_summary": "Elevated ALT levels (> upper limit of normal) were associated with an increased prevalence of severe COVID-19 complications (OR: 2.15 [95% CI, 1.43-3.23]) and showed a specificity of 77%. The mean difference in ALT levels between mild and severe COVID-19 cases was 8 U/l (95% CI, 1.0-15).", "population_specificity": "Patients affected by SARS-CoV-2 (COVID-19).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:45.920244+00:00"}
{"study_id": 103300, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review GI symptoms and liver-related biomarkers, including alanine aminotransferase levels, in SARS-CoV-2-infected individuals.", "results_summary": "The study found increased alanine aminotransferase levels in some COVID-19 patients, suggesting potential hepatic involvement, but did not focus on alanine's therapeutic effects.", "population_specificity": "SARS-CoV-2-infected individuals (18,246 patients across 43 studies).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:46.350298+00:00"}
{"study_id": 103301, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to differentiate COVID-19 from other respiratory infections (H7N9 and H1N1) by comparing clinical presentations, chest CT features, and disease progression.", "results_summary": "The study found that H7N9 and COVID-19 patients had longer hospitalizations and more severe cases than H1N1 patients, with H7N9 showing higher fatality rates. Elevated alanine aminotransferase levels were noted in H7N9 and H1N1 patients, differing significantly from COVID-19 patients.", "population_specificity": "Hospitalized patients with laboratory-confirmed SARS-CoV-2 (n=83), H7N9 (n=36), or H1N1 (n=44) infections.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:47.320861+00:00"}
{"study_id": 103302, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of pitavastatin in real-world clinical practice for patients with hyperlipidemia, focusing on its impact on lipid profiles and adverse events.", "results_summary": "Pitavastatin demonstrated dose-dependent reductions in LDL cholesterol (-23.4% to -35.2%) and was well tolerated, with only 1.74% of patients experiencing adverse events and minimal grade 2+ toxicity in alanine aminotransferase and other markers. No cases of rhabdomyolysis were reported, though 0.04% had musculoskeletal disorders.", "population_specificity": "Korean patients aged 20 or older with hyperlipidemia.", "effective_dosage": "1, 2, or 4 mg pitavastatin.", "study_duration": "Mean duration of 126 days (at least 8 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:48.599260+00:00"}
